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ABSTRACT 
The human immunodeficiency virus type 1 enhancer binding protein 1 (HIVEP1) binds to 
the NF-ĸB consensus sequence and is therefore suggested to be involved in inflammatory 
signaling cascades. We recently identified two tagging SNPs, positioned 90 kb upstream 
(rs169713) and within exon 4 (rs2228220) of the HIVEP1 gene, to be replicatively 
associated with venous thrombosis in a multistage study following GWAs (Morange et al., 
2010; Germain et al., 2011). Venous thrombosis, like other vascular diseases, is a 
common multifactorial trait involving various pathophysiological processes. In the current 
work, we analyzed the impact of distinct proinflammatory stimuli on endogenous HIVEP1 
expression and found that TNFα and IL-1β increased HIVEP1 expression in endothelial 
cells (EA.hy926) and monocytes (THP1). The TNFα-induced HIVEP1 expression could be 
dose-dependently decreased by simvastatin and to a lesser extent by rosuvastatin and 
atorvastatin, but not by pravastatin or aspirin. We demonstrated the exclusive nuclear 
localization of HIVEP1 using western blot analyzes and immunofluorescence. 
Investigation of the transcriptional regulation of HIVEP1 revealed the strongest 
transcriptional activity residing between positions -1650 and -1241 (from the transcription 
start site) in both, endothelial and monocytic cells, while an intronic modulator affected 
HIVEP1 expression in a cell type-specific manner. In addition, we observed a potential 
enhancer capacity of a 319 bp region harbouring the rs169713 T allele in EA.hy926 and 
THP1 cells. Screening of 5 kb of the HIVEP1 5'-flanking region in 57 patients with 
cardiovascular disease (MolProMD study) led to the identification of ten common genetic 
variants. Individual subcloning and resequencing of a region encompassing three adjacent 
SNPs in the strong transcriptional activity portion (-1060 to -953) revealed the existence of 
four molecular haplotypes (MolHaps): MolHap1 (A-1060-C-1037-A-953), MolHap2 
(A-1060-G-1037-A-953), MolHap3 (A-1060-G-1037-C-953) and MolHap4 (T-1060-G-1037-C-953). Using 
reporter gene assays, we observed a significantly decreased (~50%) transcriptional 
activity of MolHap4 compared to MolHap1 (p<0.001). To identify transcription factors 
involved in HIVEP1 regulation, we performed cotransfection, ChIP and EMSA 
experiments and found a transcription factor module comprising the zinc finger proteins 
SP1, WT1 and EGR1 to be involved in HIVEP1 expression regulation. Our analyses also 
suggest the involvement of the inflammatory transcription factor NF-κB in HIVEP1 
expression, which is modulated by simvastatin. Our results indicate that HIVEP1 is 
differentially regulated by transcription factors and proinflammatory cytokines, and that it 
may serve as a potential pharmacological target of statins’ pleiotropic pharmacologic 
actions. Animal and clinical studies should follow to evaluate a potential causal 
relationship between HIVEP1 expression and development of venous thrombosis. 
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1 INTRODUCTION 
1.1 Studying genetic diseases  
The predisposition of an individual to a disease often depends on both, environmental 
factors, such as nutrition, smoking and physical exercise, and genetic susceptibility. 
Classical twin studies, comparing monozygotic (identical) and dizygotic (fraternal) twins, 
are a method to analyze the contribution of environmental versus genetic factors to 
disease development, first published by Galton (Galton, 1875). Thereby, differences in 
phenotypes of monozygotic twins imply that the observed differences are due to 
environmental instead of genetic factors. By contrast, if a disease is influenced by 
heritable factors, the disease concordance would be greater in monozygotic than in 
dizygotic twins, postulated by Siemens in 1924, termed the twin rule of pathology 
(Boomsma et al., 2002). Twin studies revealed that lipoprotein(a) levels (Austin et al., 
1992), the susceptibility to certain cancers, such as prostate cancer (Grönberg, 2003; 
Ahlbom et al., 1997), and death from coronary heart disease (CHD) at younger ages 
(Marenberg et al., 1994) are genetically determined. 
The genetic component of a disease is based on genetic variants, i.e. a variation in the 
human sequence, such as single nucleotide polymorphisms (SNPs), deletions or 
insertions, in a single gene (monogenic “Mendelian” disease) as well as by common 
variants located in several genes (polygenic disease). Monogenic diseases, such as cystic 
fibrosis (Kerem et al., 1989) and Huntington disease (Gusella et al., 1983), are rare 
diseases due to evolutionary selection. Polygenic diseases are complex diseases, in 
which each common variant (minor allele frequency >1%) contributes moderately to 
disease development, termed the “common variant-weak effect-common disease” model 
(Cambien and Tiret, 2007). Complex diseases, such as cardiovascular disease (CVD), 
diabetes mellitus and dementia, are to a great extent responsible for human morbidity and 
mortality, pointing to the necessity to reveal the genetic mechanisms of complex diseases 
(Buckland, 2006).  
Two strategies exist to elucidate genetic patterns that contribute to or cause disease 
phenotypes: Family approaches (linkage analyses) and case-control studies (association 
studies). Both approaches can be subdivided into the candidate gene approach and the 
genome-wide approach, while family approaches are classical performed using the 
candidate gene approach (Brand-Herrmann, 2008). If the pathophysiology of a disease is 
well described, association studies focus on genetic variants within genes known to be 
involved in the relevant pathophysiological processes (candidate gene approach). Since 
the human genome has been sequenced (Venter et al., 2001; Lander et al., 2001) and 
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costs of high throughput methods have decreased considerably, genome-wide association 
studies (GWAs) become increasingly popular in studying complex diseases, 1183 studies 
to date (http://www.genome.gov/gwastudies/). This non-hypothesis driven approach has 
already led to the identification of variants located in genes or intergenic regions with often 
unknown contribution to the disease. 
 
1.1.1 Linkage analyses 
Linkage analyses are based on genotype and phenotype data of disease-unaffected and 
-affected family members in different generations. It addresses the question whether a 
genetic marker is accumulated in affected family members, thus cosegregates with the 
trait of interest with higher frequency than expected by chance (Cambien and Tiret, 2007). 
Biostatistical algorithms combine marker, phenotype and pedigree data to identify genetic 
variants associated with the analyzed trait. Confirmation of the association can be 
conducted by a second linkage analysis comprising a higher density of genetic markers 
(fine mapping). Linkage analyses are often limited by the small number of affected family 
members and are in the need of well-defined phenotypes. Linkage analyses have been 
used successfully to provide information on high risk variants associated with rare 
disorders (Arnett et al., 2007). For example, the susceptibility gene for familial Alzheimer 
disease, apolipoprotein E (ApoE) (Pericak-Vance et al., 1991), or for early-onset breast 
cancer, breast cancer 1 early-onset (BRCA1) (Hall et al., 1990), was identified by linkage 
analysis.  
 
1.1.2 Association studies 
Association studies are based on different frequencies of SNPs or copy number variants 
(CNVs) and haplotypes in cases compared to controls. A haplotype displays the allele 
combination of physically close SNPs on the same chromosome, which are inherited 
together based on linkage disequilibrium (LD), i.e. two alleles occur on the same 
chromosome more often than if they were unlinked. To identify a SNP or haplotype, which 
is significantly associated with the trait of interest, the frequency of SNPs or haplotypes in 
case and control samples are compared, while statistical differences between these 
groups reveal the association of a SNP or haplotype with the analyzed disorder (Arnett et 
al., 2007). Instead of testing millions of SNPs, GWAs are performed using so-called 
“tagging SNPs”. The genotype of a tagging SNP predicts those of cosegregating SNPs, if 
both SNPs are found in LD. Since the genome can be subdivided into LD segments, a set 
of well-chosen tagging SNPs is able to deliver information about most common genomic 
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variants (Hirschhorn and Daly, 2005). A limitation of GWAs is the heterogeneity of 
populations, while the advantage of GWAs is the independence from a prior biological 
hypothesis. Individual GWAs revealed a large number of CVD-associated SNPs. 
Schunkert and collegues (Schunkert et al., 2011) found 13 new susceptibility loci for 
coronary artery disease (CAD) and validated association of previously found loci to CAD. 
Several loci were identified and subsequently confirmed by GWA to influence blood 
pressure (Newton-Cheh et al., 2009; Levy et al., 2009; Ehret et al., 2011) as well as 
myocardial infarction (Kathiresan et al., 2009). A follow up study of a GWA, comprising 
cases with a documented history of venous thromboembolism (VTE), including deep vein 
thrombosis (DVT), pulmonary embolism (PE) or both, and controls of the MARseille 
Thrombosis Association study (MARTHA), FActeurs de RIsque et de récidives de la 
maladie thromboembolique VEineuse (FARIVE) study and Multiple Environmental and 
Genetic Assessment (MEGA) study, identified a susceptibility locus for venous thrombosis 
on chromosome 6p24.1, the HIVEP1 locus (Morange et al., 2010).  
 
1.2 Vascular diseases 
1.2.1 Inflammatory background of multifactorial diseases 
The final goal of the acute inflammatory response, consisting of inducers (microbial 
infections, malfunctionaling tissue), sensors (Toll-like receptors) and mediators (tumor 
necrosis factor α [TNFα], interleukin-1 [IL-1]), which affect the target tissue to react in an 
appropriate manner, is to restore normal functionality of the affected tissue, at least by the 
resolution of inflammation (Medzhitov, 2008). Once the resolution of inflammation fails, 
e.g. due to incomplete trigger elimination, an acute inflammatory state is transformed to 
chronic inflammatory conditions. Thus, persistence of allergens, unrepaired tissue 
damage, indigestible pathogens or inadequate production of resolution mediators may 
cause chronic inflammation. Nonresolving inflammation leading to the development of 
chronic inflammatory states is involved in the pathogenesis of a variety of human 
diseases, such as multiple sclerosis, asthma, cancer, obesity, neurodegenerative disease, 
rheumatoid arthritis, type 2 diabetes mellitus or vascular diseases such as atherosclerosis 
(Tedgui and Mallat, 2006; Nathan and Ding, 2010).    
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1.2.2 Endothelial function and dysfunction  
Blood vessels display a characteristic three layer, consisting of the outermost adventitia, 
predominantly containing elastic and collagen fibers, the media, characterized by smooth 
muscle cells, and the innermost intima, comprising endothelial cells (Fanghänel et al., 
2003). Venous vessels usually are composed of a thinner media and a thicker adventitia 
compared to arteries (Fanghänel et al., 2003). The vascular endothelium, composed of a 
single layer of endothelial cells, builds the primary physical barrier between blood and 
tissue in both types of vessels. Located at this position, the endothelial cells are sensitive 
to changes in plasma and interstitial fluid and therefore harbouring a pivotal role in 
modulating the function of organs (Deanfield et al., 2007). Although the 6 x 1013 human 
endothelial cells, which build an area of approximately 7000 m2 in humans (Simionescu, 
2007), are heterogenic due to their tissue location, e.g. artery or vein, they share common 
functions, such as transport of macromolecules and solutes across the endothelium, 
regulation of vascular tone, contributing to coagulation, providing of an antithrombotic 
surface and aiding during immune response (Pober et al., 2009). Von Willebrand factor, 
thrombomodulin and tissue factor pathway inhibitor are coagulation regulating molecules, 
which are produced by the endothelium. Fibrinolysis can be activated by tissue-
plasminogen activator, whose activity is in turn controlled by plasminogen activator 
inhibitor-1 (PAI-1) (Pober et al., 2009). Furthermore, prostacyclin and nitric oxide (NO) are 
important inhibitors of platelet activation and aggregation as well as inducers of 
vasorelaxation. Endothelial cells constitutively generate NO from L-arginine by the NO 
synthase (NOS). An increase in blood pressure leading to shear stress results in release 
of NO, that diffuses to vascular smooth muscle cells (VSMCs), thereby altering artery 
stiffnes by influencing the VSMC tone (Wilkinson et al., 2004). Besides its vasodilator 
property and suppressing effect on platelet activation, NO inhibits adhesion of monocytes 
at the endothelial surface by suppressing the expression of adhesion molecules and 
decreases low-density lipoprotein (LDL) oxidation. In clinical practice, NO is measured to 
reflect the state of the endothelial function (Deanfield et al., 2007).  
Endothelial dysfunction in venous and arterial vessels is triggered by mechanical or 
chemical stress leading to decreased NOS protein expression, loss of antithrombotic 
properties and increased expression of cell adhesion molecules of the endothelium. 
These changes in endothelial properties result in vascular stiffness, platelet activation and 
aggregation as well as leukocyte adhesion with subsequent penetration (Celermajer, 
1997; Saha et al., 2011). The molecular basis of vascular diseases (VD), such as 
atherosclerosis and venous thrombosis, has its basis in an early endothelial “dysfunction” 
(a term which is more often related to arterial disease).  
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1.2.3 Pathophysiology of atherosclerosis 
Atherosclerosis describes a complex, multifactorial, progressive, chronic inflammatory 
disease of large and medium-sized arteries, exhibiting formation of plaques within the 
arterial walls. Artherosclerotic plaques consist of necrotic cores and lipid accumulations, 
calcified regions, leukocytes, endothelial and foam cells as well as activated VSMCs 
(Galkina and Ley, 2009). Atherosclerosis is the primary cause of CVD comprising CAD 
and cerebrovascular disease, the most common forms of CVD (Lusis, 2000). CVD causes 
16.7 million deaths each year, therefore being the leading cause of mortality worldwide 
(Dahlöf, 2010). 
One of the first steps in the development of atherosclerotic lesions is endothelial 
dysfunction caused by multiple factors, such as elevated plasma levels of oxidatively 
modified LDL or homocysteine, infection, increased blood pressure, smoking induced 
production of free radicals or genetic factors, followed by transcytosis of lipoproteins into 
the subendothelium (Ross, 1999) (Figure 1, 1). Accumulated lipoproteins undergo 
physico-chemical modifications, such as oxidation and proteo- or lipolysis, which leads to 
activation of endothelial cells resulting in enhanced production of cytokines and 
chemokines as well as endothelial cell surface adhesion molecules (E- and P-selectin, 
intercellular adhesion molecule-1 [ICAM-1] or vascular cell adhesion molecule-1 
[VCAM-1]) (Hansson, 2005; Hansson and Hermansson, 2011) (Figure 1, 2/3). In 
particular, released proinflammatory cytokines, such as TNFα and IL-10, in turn activate 
VSMCs (Raines and Ferri, 2005) and released chemoattractant substances, such as 
monocyte chemoattractant protein-1 (MCP-1) and IL-8, lead to adherence of monocytes at 
sites of activated endothelium and subsequent migration into the subendothelium 
(Simionescu, 2007). Here, endothelial-released macrophage colony-stimulating factor 
(M-CSF) mediates differentiation of monocytes into macrophages (Hansson, 2005; Smith 
et al., 1995) (Figure 1, 4). Activated macrophages express scavenger receptors, which 
unlike LDL receptors lead to immense uncontrolled uptake of oxLDL causing 
transformation of macrophages into foam cells (Ross, 1993) (Figure 1, 5). The so-called 
“fatty streaks”, consisting of lipid-laden foam cells, endothelial lipid accumulation and 
T-cells, are characteristic for early atherosclerotic lesions (Hansson and Hermansson, 
2011). The progress of plaque formation is mediated by cytokines, growth factors, tissue 
factor and interferon-γ (IFN-γ) causing proliferation and infiltration of VSMCs from the 
media through the internal elastic lamina into the intima of the artery (Plutzky, 2003). 
Subsequently, VSCMs generate extracellular matrix proteins such as collagen. In this 
way, a fibrous cap is developed by several VSMCs embedded in layers of connective 
tissue, e.g. elastic fibers and collagen, to cover the lipid and necrotic core of the 
atherosclerotic plaque (Plutzky, 2003; Ross, 1995) (Figure 1, 6/7). Plaque progression 
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Media
Intima
Endothel
and continuous thickening by infiltration of patrolling T cells, macrophages and mast cells 
at the shoulder of the plaque, synthesizing proinflammatory mediators (TNFα, IFNγ, IL-4) 
and enzymes (proteases) (Hansson and Robertson, 2006), are characteristic for later 
stages of atherosclerotic lesions (Figure 1, 8).  
Figure 1: Stages of the atherosclerotic lesion (1) LDL particles accumulate at the surface of the 
endothelium. Subsequently, transcytosis and oxidation of LDL trigger the production of 
proinflammatory cytokines (IL-1) and chemokines (MCP-1) (2). (3) Expression of cell surface 
adhesion molecules and chemokines leads to attachment of monocytes, followed by migration into 
the subendothelium and to differentiation into macrophages (4). (5) Massive uptake of oxLDL by 
scavenger receptor expressing macrophages results in foam cell formation (fatty streaks). (6 and 7) 
Release of cytokines and growth factors mediates activation and proliferation of VSMCs, migrating 
out of the media into the intima. VSMCs produce extracellular matrix, which contributes to 
formation of a fibrous cap. (8) Later stages of atherosclerotic lesions are characterized by 
infiltration of patrolling T cells, mast cells and further macrophages, leading to an atherosclerotic 
plaque, containing a lipid and necrotic core. LDL, low-density lipoprotein; IL-1, interleukin-1; MCP-
1, monocyte chemoattractant protein-1; VSMCs, vascular smooth muscle cells (adapted and 
printed with permission from Plutzky 2003). 
The stability of an atherosclerotic plaque depends on the balance between matrix 
synthesis and degradation, numbers of infiltrating cells at the plaque's shoulders as well 
as on hemodynamic forces, especially at arterial branches (Shah, 2003). Clinical 
symptoms may already occur before plaque rupture, since growing atherosclerotic 
plaques narrow the vessels lumen (Hansson and Hermansson, 2011). Once a plaque 
rupture occurs due to fissuring, erosion or ulceration, the highly thrombotic substances of 
the plaque’s lipid core are exposed and thrombus formation is immediately initiated at the 
vessel’s surface by platelet aggregation and humoral coagulation. Thus, atherothrombosis 
in peripheral, coronary or cerebral arteries provokes gangrene, myocardial infarction or 
stroke, respectively, by critically reducing any further blood flow at sites of thrombus 
formation or in distal regions due to embolus formation (Hansson and Hermansson, 
2011).  
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1.2.4 Venous thrombosis 
In contrast to arterial thrombosis, venous thrombosis (VT) arises in the venous system, 
initiated primarily at the venous valves (Esmon, 2009). The incidence of symptomatic and 
objectively confirmed VTE is 2 to 3 per thousand inhabitants and varies strongly with age 
from 0.1 in adolescence to 8 per 1000 in ≥80-year-olds (Naess et al., 2007). Deep injury 
of the vessel wall may not be a common feature in VT as in arterial thrombosis, though 
mechanical (stretch or surgery) or chemical (sepsis) stress may activate the endothelium 
leading to an increased expression of cytokines and procoagulant proteins (tissue factor) 
as well as adhesion molecules, promoting thrombus formation (Saha et al., 2011). Since 
inflammation decreases endothelial production of antithrombotic thrombomodulin and 
PAI-1, while increasing tissue factor and fibrinogen, inflammation is thought to influence 
thrombogenesis (Wakefield et al., 2008). The initial trigger of thrombus formation in the 
venous system is under debate. However, in 1856 already, Virchow postulated a triad of 
causes, which lead to the development of VT: 1) changes in blood coagulability, as shown 
for alterations in genes, which lead to increased blood coagulation, such as factor V 
Leiden, prothrombin or factor VII (Zee et al., 2009), 2) alterations in the vessel wall, as 
one thrombosis initiating factor is trauma-derived injury of the vein wall leading to 
endothelial damage, and 3) stasis, occurring primarily at venous valves inducing hypoxia 
due to hemoglobin desaturation, leading to endothelial activation (Lopez et al., 2004). 
Activated endothelial cells express the cell surface adhesion molecules E- and P-selectin 
to recruit leukocytes or tissue factor-rich microparticles (MPs) to the region of stasis, 
where they initiate the thrombus formation cascade. MPs are phospholipid vesicles 
derived from leukocytes, platelets or endothelial cells. Tissue factor-bearing MPs express 
P-selectin-glycoprotein ligand-1 (PSGL-1) on their surface to interact with the activated 
endothelium or with platelets (Polgar et al., 2005; Myers et al., 2003). Subsequently, 
release of tissue factor to the endothelial cells triggers the coagulation reactions on the 
phosphaditylserine-rich activated endothelial cell surface (Figure 2). The coagulation 
cascade starts by the zymogen X, which is converted by the serine protease VIIa to the 
active enzyme Xa. Fusion of Xa and Va mediates conversion of prothrombin (II) to 
thrombin (IIa) (Lopez et al., 2004). The prothrombotic protease thrombin in turn leads to 
activation of further coagulation factors, such as XIa or VIIIa, platelet activation and fibrin 
formation. Fibrin deposition occurs and platelets, arriving at the fibrin clot, contribute to 
thrombus growth (Wu and Thiagarajan, 1996), leading to clinical manifestations such as 
DVT, which may cause PE. 
Thrombus resolution involves recruitment of neutrophils and leukocytes, mediating 
fibrinolysis and collagenolysis as well as phagocytosis (Wakefield et al., 2008). 
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Figure 2: Model for venous thrombosis The activated endothelium upregulates expression of    
P- and E-selectin. Leukocyte-derived tissue factor-loaden microvesicles attach to the cell surface 
by interaction of PSGL-1 and endothelial selectins. Release of tissue factor to endothelial cells 
triggers the activation of the enzymatic coagulation cascade, resulting in thrombin synthesis and 
fibrin accumulation. PSGL-1, P-selectin glycoprotein ligand-1; TF, tissue factor; factor II, 
prothrombin; IIa, thrombin (with permission from Lopez et al., 2004).      
 
1.2.5 Therapeutic effects of antiinflammatory drugs 
In this work, we concentrated on two main drugs for the therapy of chronic inflammatory 
disorders: acetylsalicylic acid (e.g. aspirin) and 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase inhibitors (statins).  
Aspirin is an antiinflammatory cyclooxygenase (COX) inhibitor, which mediates its 
antiinflammatory property in part by inhibition of the nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB) activation, an important mediator of inflammation 
(Yin et al., 1998).  
Large clinical trials demonstrated the beneficial effects of drug treatment with statins in the 
primary and secondary prevention of CHD, a major manifestation of atherosclerosis (Liao 
and Laufs, 2005). As HMG-CoA reductase inhibitors, statins lower the cholesterol 
synthesis by binding to the active site of the HMG-CoA-reductase, the rate limiting 
enzyme in hepatic cholesterol biosynthesis (Istvan and Deisenhofer, 2001; Goldstein and 
Brown, 1990). Reduced cellular cholesterol levels lead to upregulation of the LDL 
receptor, followed by an increased hepatic uptake of apolipoprotein B-containing 
lipoproteins (very-low-density lipoproteins [VLDL], intermediate-density lipoproteins [IDL], 
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LDL), thereby positively modifying the balance between antiatherogenic high-density 
lipoprotein (HDL) and atherogenic LDL through an elevation of HDL (Sposito and 
Chapman, 2002). Since the cholesterol level is associated with CHD (Klag et al., 1993), 
the positive effect of statins on the risk for CHD is attributed to their cholesterol, thus LDL 
lowering capacity. Clinically used statins are lovastatin, pravastatin, simvastatin, 
fluvastatin, atorvastatin, cervistatin, pitastatin and rosuvastatin. The various statins share 
the HMG-like moiety, while they differ in their tissue permeability, metabolism and 
efficiency to inhibit extrahepatic HMG-CoA reductase (Liao and Laufs, 2005).  
Besides the cholesterol lowering effect of statins, several so-called “pleiotropic”, 
cholesterol-independent effects (Figure 3) have been described, which are in part based 
on the inhibition of the synthesis of the isoprenoid intermediates geranylgeranyl-
pyrophosphate (GGPP) and farnesyl-pyrophosphate (FPP), mevalonic acid downstream 
products, among the endproduct cholesterol (Hansson, 2005). By a process termed 
prenylation, GGPP and FPP are attached to proteins, for which prenylation is necessary 
to attach to the cell membrane and their biological functionality. As statins are able to 
decrease the prenylation, they subsequently inhibit activation of the small guanosine 
triphosphate (GTP)-binding protein Ras and Ras-like proteins, such as Rho (Guijarro et 
al., 1998). Reduction of active Rho leads to reduction of NF-kB activity (Sposito and 
Chapman, 2002). Furthermore, animal studies have shown that statins inhibit recruitment 
of monocytes by downregulation of surface adhesion molecules, e.g. P-selectin, due to 
restorage of NO production (Lefer et al., 1999; Scalia et al., 2001), demonstrating 
additional antiinflammatory properties of statins. In addition, in clinical studies, such as the 
Cholesterol and Recurrent Events (CARE) study or the Air Force/Texas Coronary 
Atherosclerosis Prevention Study (AFCAPS/TexCAPS), statin treatment resulted in 
decreased levels of C-reactive protein, a clinical marker for systemic inflammation 
(Mizuno et al., 2011). The endothelial function is improved by statin use, since statins 
enhance the mRNA stability of endothelial NOS (Laufs and Liao, 1998), thereby 
increasing the endothelial production of NO, which permitts vasodilatation. Statins also 
decrease endothelin-1 expression, a potent vasoconstrictor, and the synthesis of reactive 
oxygen species (ROS) (Takemoto and Liao, 2001). The antiproliferative property of statins 
is attributed to the above mentioned accumulation of inactive Rho and Ras, which are 
involved in cell cycle regulation, as well as to the statin-mediated inhibition of VSMC 
proliferation, which in turn improves plaque stability (Liao and Laufs, 2005). Statins have 
been shown to mediate plaque stability, since they - besides their lipid lowering effect - 
have been shown to inhibit expression of matrix metalloproteinases (MMPs), which 
degrade the plaque matrix (Aikawa et al., 2001). Several statins modulate thrombogenesis 
by suppressing expression of tissue factor, the initiator of intravascular thrombus 
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formation (cf. chapter 1.2.4) (Colli et al., 1997). The coagulation activity of factor VII and 
the factor V dependent prothrombin activation are reduced upon statin application (Undas 
et al., 2001), while tissue plasminogen activator expression is increased in contrast to 
downregulation of its inhibitor (PAI-1) by endothelial cells (Bourcier and Libby, 2000). 
Additionally, platelet aggregation can be suppressed by statins, possibly by decreasing 
the cholesterol amount in the platelet membrane in combination with a reduced 
thromboxane A2 (TXA2) production (Sposito and Chapman, 2002), all together pointing to 
an antithrombotic property of statins.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Pleiotropic effects of statins Overview of the cholesterol-independent impact of statins 
on vascular wall cells, which reduces the risk for cardiovascular diseases. Statins inhibit platelet 
activation, promote fibrinolysis and strengthen the plaque stability. Vascular inflammation is 
diminished, endothelial function is improved, and vasoconstriction as well as proliferation of 
vascular SMCs is suppressed by statins. TXA2, thromboxane A2; FV or VII, coagulation factor V or 
VII; tPA, tissue plasminogen activator; PAI-1, plasminogen activator inhibitor-1; MMPs, matrix 
metalloproteinases; TF, tissue factor; CRP, C-reactive protein; ROS, reactive oxygen species; NO, 
nitric oxide; SMC, smooth muscle cell; ET-1, endothelin-1 (modified from Takemoto and Liao, 
2001).  
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1.3 Control of eukaryotic gene expression 
The sequence of the human genome is known since 2001 (Venter et al., 2001; Lander et 
al., 2001). Approximately 1.5% of the genome was discovered to be protein coding, 45% 
to be repetitive DNA, while the function of the remaining approximately 50% of the 
genome is still subject to scientists’ work. However, a large body of evidence suggests 
involvement of these noncoding sequences in gene expression regulation, harbouring 
important cis-regulatory elements, which are recognized by diverse transcription factors 
(Heintzman and Ren, 2009). The precise interplay of trans-acting factors is essential for 
the proper spatial and temporal gene expression in order to provide accurate execution of 
biological processes (Maston et al., 2006). Eukaryotic transcription can be controlled at 
different levels: accessibility of DNA sequence, transcription initiation and elongation, 
mRNA processing, transport and stability, and translation. 
 
1.3.1 Cis-active transcriptional regulatory elements 
Transcriptional cis-regulatory elements are subdivided into two classes: proximal or core 
regulatory elements and distal regulatory elements, such as enhancer, silencer and 
insulator. These regulatory elements harbour binding sites for the molecular machinery 
encompassing basic or general transcription factors (GTFs), activators and coactivators 
(Maston et al., 2006).  
 
1.3.1.1 Core promoter – proximal regulatory elements  
The core promoter surrounds the transcription start site (TSS) and defines the direction of 
transcription. The regulatory elements, which are required for assembling of the 
preinitiation complex, guiding the RNA Polymerase II upstream of the TSS to transcribe 
the gene, are located in the core promoter (Smale and Kadonaga, 2003). Several 
characteristic core promoter elements (TATA box, Inr, DPE, BRE, MTE) are located in a 
~100 bp zone surrounding the TSS and are recognized by GTFs (Ohler and Wassarman, 
2010) (Figure 4). Not all of the core promoter elements are present in every core 
promoter, the TATA box, for example, is only found in 10-16% of vertebrates’ promoters 
and the initiator (Inr) is the most common core element, represented in 55% of promoters 
(Heintzman and Ren, 2007; Table 1).    
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Core element Position relative to TSS* Consensus sequence** Frequency in promotersFlies              Vertebrates
TATA approx. -31 to -26 TATAWAAR 33-43%           10-16%            
Inr -2 to +4 YYANWYY 69%                  55%
DPE +28 to +32 RGWYV 40%                  48%
BRE approx. -37 to -32 SSRCGCC - 12-62%
MTE +18 to +29 CSARCSSAACGS 8.5%                 -
Core promoter elements
Enhancer region Proximal region -37 -31 -26 -2 +4 +18 +28 +32
BRE TATA INR MTE DPE
 
 
 
 
 
 
Figure 4: Transcription regulatory elements General transcription factors (GTFs) interact with 
specific core promoter elements (TFIIB recognition element [BRE], TATA box [TATA], initiator [Inr], 
motif ten element [MTE], downstream promoter element [DPE]), surrounding the transcription start 
site (TSS, black arrow). Numbers indicate position of core promoter elements relative to the TSS 
(counted in bp). Activators (orange oval and yellow diamond) bind to specific consensus sites in 
proximal or distal enhancer regions and interact (green arrows) with GTFs (blue rectangle and 
horseshoe) and coregulators (green hexagon). Coregulators may interact (blue arrows) with the 
general transcription machinery, chromatin-modifiers or nucleosomes (green). Pol II, RNA 
Polymerase II (adapted and printed with permission from Fuda et al., 2009).  
Table 1: Sequences and frequencies of core promoter elements 
              (adapted from Heintzman and Ren 2007)   
 
 
 
 
 
 
 
* Transcription start site (TSS) is assigned to position +1.  
**Degenerate nucleotides represented using IUPAC codes. 
 
The first identified core promoter element was the TATA box, an A/T-rich sequence 
positioned 26-31 bp upstream of the TSS and bound by a subunit of the transcription 
factor IID (TFIID), the TATA-binding protein (TBP) (Burley, 1996). Independent of the 
TATA box, the TSS surrounding Inr is able to trigger accurate transcription (Smale and 
Baltimore, 1989), while TATA box and Inr work synergistically, when they exist together in 
one core promoter (Smale et al., 1990). The Inr consensus sequence is bound by 
subunits of TFIID, TBP-associated factors 1/2 (TAF1 and TAF2) (Chalkley and Verrijzer, 
1999). A third core promoter element, primarily present in TATA-less promoters, is the 
downstream promoter element (DPE), located 28-32 bp downstream of the TSS. The DPE 
is recognized by TAF6 and TAF9 and is, like the TATA box, suggested to be able to 
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communicate with enhancer regions (Butler and Kadonaga, 2001). The element first 
identified to be situated upstream of the TATA box, at positions -37 to -31 relative to TSS 
and recognized by TFIIB instead of TFIID, is the TFIIB recognition element (BRE) 
(Lagrange et al., 1998). But further studies found the BRE element to be located either 
up-or downstream of the TATA box (BREu and BREd), the position determining its 
repressive or active function (Deng and Roberts, 2006). Another core element is the motif 
ten element (MTE), at positions +18 to +29 downstream of the TSS, which needs to 
interact with the Inr motif to promote transcription and is able to compensate the function 
of mutated TATA box or DPE (Lim et al., 2004).   
Beside these core elements, the existence of stretches (0.5 to 2 kb) of the CG 
dinucleotide, termed “CpG islands”, is a common feature in many often TATA-less 
promoters (Blake et al., 1990). The highest GC content was shown to be distributed to the 
5’-untranslated region (5’-UTR), the TSS and the first 1000 bp upstream of the TSS. 
Housekeeping genes are mostly driven by CpG islands promoters, while differently 
regulated genes rather harbour TATA-boxes in their promoter region (Jaksik and 
Rzeszowska-Wolny, 2012). The majority, i.e. approximately 70% (Saxonov et al., 2006), 
of mammalian genes is under the control of CpG island promoters, while the minority is 
regulated by TATA-box comprising promoters (Carninci et al., 2006). Metyhlation occurs 
at CG dinucleotides, while CpG islands are predominantly nonmethylated and recruit 
proteins to provide an accessible chromatin state for transcription initiation. However, 
metyhlation of CpG islands resulting in gene silencing may occur during cell differentiation 
and is considered to be involved in the development of cancer (Deaton and Bird, 2011). 
 
1.3.1.2 Distal regulatory elements 
The distal regulatory elements encompass enhancer, silencer and insulator. Enhancers 
mostly harbour clusters of transcription factor binding sites (TFBS) and action in a 
distance- and orientation-independent manner (Maston et al., 2006). Thus, they may be 
located several hundreds of kilobase pairs up- or downstream of the TSS, as shown for 
the three interleukin genes IL-4, IL-13 and IL-5, which are spread over 120 kb and are 
controlled by one regulatory element (Loots et al., 2000). The favored mechanism by 
which the distant enhancer element can interact with the core promoter region is 
“DNA-looping” (Vilar and Saiz, 2005). Enhancers possess different mechanisms to 
enhance transcription of the core promoter. First of all, enhancers may modify the 
chromatin structure. The basic unit of the chromatin is the nucleosom, which consists of 
~146 bp of DNA wrapped around a histone octamer complex, harbouring two H2A-H2B 
dimers and one H3-H4 histone tetramer (Luger et al., 1997). By recruitment of the 
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nucleosome-remodeling complex comprising SWI//SNF proteins, the position of 
nucleosomes at the DNA is altered in an adenosine triphosphate (ATP)-dependent 
manner, allowing easier access of the transcription machinery to the core promoter to 
activate transcription (Kingston and Narlikar, 1999). A second mechanism to promote 
transcription is the recruitment of protein complexes, which leads to histone-acetylation, 
resulting in decondensation of the chromatin (Heintzman and Ren, 2009). At least, 
enhancers may interact with the mediator complex, connecting activators binding at the 
enhancer region with GTFs to initiate transcription (Myers and Kornberg, 2000). 
Silencers, as enhancers, work in an orientation- and distance-independent manner, but 
repress gene transcription instead of enhancing it, thus containing consensus sites for 
repressors (Ogbourne and Antalis, 1998). An activator may switch to a repressor by 
interaction with repressive coactivators. Repressors inhibit transcription by competition 
with activators at consensus sites, as shown for specificity protein 1 and 3 (Li et al., 2004), 
or by direct inhibition of the activator (Harris et al., 2005). In contrast to enhancers, 
silencers may recruit complexes to mediate chromatin stability (Srinivasan and Atchison, 
2004).  
Insulators or boundary elements form a wall between neighboring genes and their 
gene-specific regulatory element to prevent that one gene is affected by the transcription 
machinery of the nearby gene (Maston et al., 2006). Insulators function in a 
position-dependent but orientation-independent manner. On the one hand, they are able 
to block the spread of repressive chromatin (heterochromatin-barrier activity). On the 
other hand, an insulator may inhibit activation of transcription by catching an activator and 
thereby preventing this factor from binding at its target promoter to enhance transcription, 
termed enhancer-blocking activity (Maston et al., 2006).    
 
1.3.2 Eukaryotic transcription 
1.3.2.1 Modification of the chromatin structure 
The first rate limiting step of transcription is the access of the transcriptional machinery to 
the DNA sequence, whereby the local chromatin structure at promoters plays a pivotal 
role (Mellor, 2005). Studies in yeast demonstrated the association of active promoters with 
nucleosome-free regions (NFR) (Lee et al., 2004). Yuan et al. (Yuan et al., 2005) 
suggested the region ~150 to ~200 bp upstream of the start codon to be characterized by 
nucleosome depletion and flanked on both sides by nucleosomes. Heintzman and Ren 
(Heintzman and Ren, 2007) confirmed that NFR also exist in humans, which is in 
accordance to observations of increased chromatin accessibility at regulatory elements 
(Felsenfeld, 1996), pointing to an evolutionarily conserved mechanism of nucleosome 
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depletion at active promoters. In addition, histone modifications seem to be associated 
with regulatory and transcribed regions. A conserved mechanism, which comes along with 
active genetic regions, is acetylation of histone H3 and H4 (Roh et al., 2005). Acetylation 
of lysine residues of histones is a reversible modification conducted by histone 
acetyltransferases (HATs) and histone deacetylases (HDACs). As mentioned above, the 
transfer of HATs to regulatory regions is mediated by transcription factors and increased 
by enhancers. On the other hand, methylation of histones is executed by histone 
methyltransferases (HMTs), adding one to three methylgroups to lysine (K) residues. A 3’ 
to 5’ gradient of H3K4 methylation was observed within transcribed regions peaking in 
trimethylation at the 5’-end (Pokholok et al., 2005). Methylation also occurs in CpG islands 
by modification of cytosines. Depending on the methylated residue, methylation may 
result in activation or repression of transcription (Heintzman and Ren, 2007). Taken 
together, active promoter regions are characterized by NFR, H3/H4 acetylation and 
trimethylation of H3K4.      
 
1.3.2.2 The transcription cycle 
Figure 5: Steps of the eukaryotic   
transcription cycle (1) An activator  
(orange oval) recruits nucleosome  
remodellers to decondensate the 
chromatin. A second activator (yellow  
diamond) recruits GTFs (blue 
rectangle) and coactivators (green 
hexagon), leading to entry of Pol II (red 
rocket) and PIC assembling (2). (3) 
DNA is unwound at TSS, transcription 
is initiated. (4) Pol II escapes from the 
promoter, transcribes up to 50 bases 
(RNA, purple line) and is  
phosphorylated to pause, mediated by                         
SPT4/5 (pink pentagon) and NELF 
(purple cycle). (5) Hyperphosphorylation by P-TEFb (blue triangle) results in escape from pausing. 
(6) Elongation, the entire gene is transcribed until termination (7) leads to release of Pol II, which 
can initiate a new transcription cycle (8). GTFs, general transcription factors; Pol II, RNA 
Polymerase II; PIC, preinitiation complex; NELF, negative elongation factor; P-TEFb, positive 
transcription elongation factor b (adapted and printed with permission from Fuda et al., 2009). 
The eukaryotic transcription cycle can be subdivided into eight major steps (Figure 5), 
which may be controlled and influenced by activators to modulate the rate of transcription 
1 Introduction 
16 
 
(Fuda et al., 2009). First of all, the transcription machinery has to gain access to the DNA 
sequence, implying chromatin remodeling (step 1), as described above (cf. chapter 
1.3.2.1). Then preinitiation complex (PIC) can be assembled (step 2), which may occur in 
two different ways: the sequential assembly pathway or the RNA Polymerase II (Pol II) 
Holoenzyme pathway (two-component). The sequential pathway starts with binding of 
TFIID to the TATA box. This interaction is stabilized by the following entry of TFIIA and 
TFIIB, leading to attachment of Pol II and TFIIF. At last TFIIE and TFIIH join the stable 
TFIID-TFIIA-TFIIB-Pol II/TFIIF-promoter complex to finish the PIC assembling (Thomas 
and Chiang, 2006). The two-component pathway suggests preformation of complexes 
harbouring GTFs and Pol II (for details refer to Thomas and Chiang, 2006). In the next 
step, the DNA surrounding the TSS is unwound, the transcription bubble is built and 
transcription is initiated by Pol II (step 3). Pol II then escapes from the core promoter, 
produces 20-50 bases of RNA downstream of the TSS (step 4) and pauses due to 
phosphorylation by the negative elongation factor (NELF). Further hyperphosphorylation 
and dissociation of NELF leads to escape of the Pol II from pausing in order to elongate 
transcription (step 5). Pol II transcribes the entire gene (step 6), following termination and 
consequent release of RNA and Pol II from the DNA (step 7), which can initiate a new 
transcription cycle (step 8) (Fuda et al., 2009).  
 
1.3.2.3 Posttranscriptional control by microRNA  
Eukaryotic gene expression can be controlled at different levels (cf. chapter 1.3). Besides 
the first control point, the accessibility of the transcription machinery to the DNA, 
eukaryotic gene expression can be regulated at last posttranscriptionally by small 
noncoding RNAs (ncRNAs), especially by microRNAs (miRNAs) (He and Hannon, 2004). 
miRNAs are small ncRNAs of 21 to 25 nucleotides, deriving from larger precursors, which 
are characterized by imperfect stem loop structures (Bartel, 2004). The mature miRNA is 
assembled in a RNA-induced silencing complex (RISC), containing Argonaute proteins, 
harbouring endonuclease activity for cleavage of the target mRNA. Usually, the 3’-UTR of 
a target gene is recognized by the RISC, which leads to mRNA degradation or translation 
inhibition. About 60% of protein coding genes are considered to be posttranscriptionally 
regulated by miRNAs (Esteller, 2011). The gene silencing effect of miRNAs is technically 
used to mediate a precise knockdown of the gene of interest. Thereby, miRNA can be 
synthetically produced as a small interfering RNA (siRNA) duplex, comprising 21 to 23 
nucleotides complementary to the target mRNA, or as a vector based short hairpin RNA 
(shRNA) (Rao et al., 2009). siRNA duplexes are delivered by transfection as well as 
shRNA expression vectors, which continuously produce shRNA in the transfected cell. 
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1.4 Transcription factor human immunodeficiency virus type 1 
enhancer binding protein 1 (HIVEP1) 
1.4.1 Transcription factor families 
Transcription factors (TFs) represent the largest most varying class of DNA-binding 
proteins. They are responsible for tissue- and stimuli-specific gene regulation in order to 
mediate cell growth, differentiation and development. TFs often harbour two domains: a 
DNA-binding domain and an activation domain, to act in response to certain stimuli, such 
as growth or inflammation. On the basis of their related primary sequence and 
three-dimensional structure of the DNA-binding domain, TFs are subdivided into diverse 
groups harbouring a specific DNA-binding-motif, such as the helix-turn-helix, 
helix-loop-helix, leucine zipper, homeodomain, steroid receptor or zinc finger motif (Pabo 
and Sauer, 1992; Latchman, 1997). Besides the diversity of DNA-binding motifs of TFs, 
some overall principles of site-specific recognition are suggested: 1) Contacts to the 
bases and DNA-backbone is essential, 2) hydrogen bonding is crucial for recognition, 3) 
side chains mediate the critical contacts, 4) protein folding and docking at the DNA severe 
correct position of side chains, 5) interactions take place into the major groove, especially 
with purines, 6) DNA-binding motifs often contain α-helices, fitting in the major groove, 7) 
hydrogen bonds and/or salt bridges mediate the contact to the DNA-backbone, 8) 
site-specific recognition implies multiple DNA-binding domains and 9) hydration and 
sequence-specific aspects of the DNA structure may be critical for recognition (Pabo and 
Sauer, 1992).  
 
1.4.1.1 Zinc finger proteins 
Zinc (Zn) finger containing proteins contribute to several cellular processes, such as 
development, differentiation and tumor suppression, and represent ~1% of all mammalian 
proteins, displaying the largest family of regulatory proteins in mammals (Iuchi, 2001). 
There exist 8 classes of Zn finger proteins, which differ in nature and distribution of their 
Zn-binding residues and their ability to bind DNA or RNA or to mediate protein-protein or 
protein-lipid interactions (Krishna et al., 2003). One single Zn finger domain is unable to 
bind to the DNA, resulting in the presence of at least two, but mostly multiple Zn fingers in 
one Zn finger protein. The Zn finger domain is characterized by one (or more) central Zn 
ion, which is (are) bound by conserved cysteine (Cys) or histidine (His) residues (Klug and 
Rhodes, 1987). The “classical” C2H2 Zn finger represents the major group of Zn fingers in 
the human genome, consisting of one Zn ion, that is bound by two Cys and two His 
residues (Miller et al., 1985). The C2H2 Zn finger was first identified in the Xenopus TFIIA 
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(Miller et al., 1985), and the consensus sequence described is Cys-X2-4-Cys-X12-His-X3-5-
His (Pabo and Sauer, 1992). The folded structure is composed of a 12 residue α-helix, 
harbouring the two His and a β-sheet hairpin, the two Cys residing in its turn (Pavletich 
and Pabo, 1991). To bind to the DNA, the N-terminus of the α-helix lies in the major 
groove and protein-DNA interactions may be executed by DNA phosphates, interacting 
with arginine and serine side chains as well as with the first Zn-coordinating His by 
hydrogen bond formation (Harrison, 1991). Additionally, a set of hydrogen bonds between 
guanine and arginine or histidine mediates the contact between the DNA and Zn finger 
(Pabo and Sauer, 1992).  
Besides the common Zn finger motif, there exist several other DNA-binding domains, such 
as the Rel homology domain, characteristic for the NF-κB family.  
 
1.4.1.2 Inflammatory transcription factors: The NF-κB family 
Members of the NF-κB transcription factor family, which is conserved from the phylum 
Cnidaria to humans (Gilmore, 2006), coordinate the expression of a variety of genes 
involved in cell proliferation, apoptosis, immune response and inflammatory diseases, 
such as multiple sclerosis and rheumatoid arthritis (Li and Verma, 2002). In contrast to 
non-atherosclerotic vessels, activated NF-κB is found in SMCs and macrophages, 
infiltrating atherosclerotic lesions, linking activated NF-κB signaling to CVD (Brand et al., 
1996).  
The NF-κB family can be subdivided into two groups: NF-κB and Rel proteins. The “NF-κB 
subfamily” encompasses the two TFs p50 and p52, which arise from processed p105 and 
p100, respectively. p105 and p100 harbour copies of ankyrin repeats, inhibiting their 
function, while they share with “Rel proteins” (RelA (p65), c-Rel, and RelB) the N-terminal 
DNA-binding/dimerization Rel homology domain (RHD) (Gilmore, 2006). In addition, Rel 
proteins contain the transactivation domain (TAD) to interact with GTFs TBP or TFIIB and 
coactivators (Schmitz et al., 1995; Sheppard et al., 1999), positively mediating gene 
expression, while p50 and p52 need coactivators or another NF-κB member for initiating 
gene expression. The activity of NF-κB is strongly controlled, as inactive NF-κB is 
maintained in the cytoplasm in a complex with inhibitor of kappa B (IκB) proteins (IκBα, 
IκBβ or IκBε) or the precursor p100 or p105 (Hayden and Ghosh, 2008). IκBs are 
distributed to different tissues and distinct NF-κB dimers. IκBα, as an example, covers the 
nuclear location signal (NLS) and interacts with DNA binding sites (Gilmore, 2006). The 
recognition site (κB-site) of all NF-κB TFs consists of 9 to 10 bp and is highly variable 
(5’-GGGRNWYYCC-3’; R, purine; N, any nucleotide; W, A or T; Y, pyrimidine) (Hoffmann 
et al., 2006). All NF-κB proteins form homo- and heterodimers, except for RelB, which 
1 Introduction 
19 
 
Auto-regulation
m
TNFα
IL-1
Canoncial Pathway
m
BAFF
CD40
Noncanoncial Pathway
generates only heterodimers, while the major heterodimer in vivo is p50-RelA (Gilmore 
2006).  
There are two major pathways leading to NF-κB activation: The canoncial (classic) and 
the non-canoncial pathway (Chen and Greene, 2004; Figure 6). Both pathways lead to 
activation of IκB kinases (IKKs) and finally to degradation of IκBs or p100/p105, which 
results in release and translocation of the NF-κB dimer into the nucleus to regulate gene 
expression. In the canonical pathway (Figure 6), NF-κB dimers, such as p50/RelA, are 
maintained in the cytoplasm associated to IκBα. Binding of ligands to their receptors, e.g. 
TNFα to the TNF-receptor, leads to recruitment of adaptors, as TNF receptor-associated 
factors (TRAFs), which play a central role in receptor-induced IKK activation (Devin et al., 
2001). IKK1 and IKK2, also termed IKKα and IKKβ, are associated with the regulatory 
scaffold NF-κB essential modifier (NEMO) to form the IKK complex (Krappmann et al., 
2000). Subsequently, IKK2 phosphorylates serine residues of IκBα, resulting in its 
ubiquitylation and subsequent degradation by the 26S proteasome, which leads to release 
and translocation of p50/RelA into the nucleus (Chen and Greene, 2004). The NF-κB 
dimer regulates transcription of various genes, including the IκBα gene, providing a 
negative feedback mechanism of the canoncial NF-κB activation pathway. 
 Figure 6: Pathways for NF-κB 
activation In the canoncial pathway, 
activation of the IKK complex (IKK1/2 
and NEMO) by TNFα or IL-1 leads to 
phosphorylation, subsequent 
ubiquitylation and degradation of 
IκBα, resulting in the release and 
translocation of NF-κB dimer 
p50/RelA into the nucleus, mediating 
gene expression. Negative feedback 
regulation is executed by activation of 
the IκBα gene. NIK activation in the 
non-canoncial pathway by BAFF, for 
example, activates IKK1, which in 
turn phosphorylates the RelB/p100 
dimer. The following p100 processing 
generates p52, and the p52/RelB dimer is translocated into the nucleus to promote target gene 
expression. TNFα, tumor necrosis factor α; IL-1, interleukin 1; IKK, IκB kinase; NEMO, NF-κB 
essential modifier; NIK, NF-κB-inducing kinase; BAFF, B-cell activating factor (adapted and printed 
with permission from Chen and Greene, 2004).  
1 Introduction 
20 
 
The non-canoncial pathway (Figure 6) mainly activates the p100/RelB complex and is 
mediated by certain receptors, such as B-cell activating factor (BAFF) or CD40 (Gilmore 
2006). In this pathway, the IKK complex does not involve NEMO and only consists of 
IKK1. Ligand-binding activates the NF-κB-inducing kinase (NIK), which phosphorylates 
and activates IKK1, leading to phosphorylation of p100 of the p100/RelB dimer. 
Subsequent ubiquitylation and degradation of p100 results in p52 generation (Amir et al., 
2004). In turn, the active p52/RelB heterodimer translocates into the nucleus to regulate 
target gene expression (Chen and Greene, 2004).  
NF-κB target genes can be classified into two groups, depending on the chromatin 
structure of their promoter region. Chromatin remodeling is not necessary for constitutively 
and immediately accessible promoters, while stimulus-dependent genes require chromatin 
modification for gene expression (Natoli et al., 2005), suggesting chromatin modification to 
be involved in NF-κB selectivity (Smale, 2011). As an example, IL1-β stimulation leads to 
acetylation of histone H4 in the granulocyte-macrophage colony-stimulating factor 
(GM-CSF) promoter, permitting access of Pol II and transcription initiation (Ito et al., 
2000). Major target genes for NF-κB dimers are genes encoding proinflammatory 
cytokines, chemokines, adhesion molecules, inducible NOS, MMPs and COX2. It is still 
discussed, whether NF-κB increased proinflammatory gene expression is the result of or 
trigger for increased NF-κB activity (Li and Verma, 2002).  
Besides IκB degradation and NF-κB transport into the nucleus, full activation of the NF-κB 
pathway requires distinct posttranslational modifications, including phosphorylation and 
acetylation (Chen and Greene, 2004). Phosphorylation of the NF-κB dimer enables the TF 
to interact with coactivators or directly enhances its transcriptional response. In case of 
RelA, phosphorylation of distinct serines enhances binding of the coactivators 
CREB-binding protein (CBP) and p300 to RelA, resulting in easier displacement of 
repressive histone deactylase complexes from promoter regions of target genes (Zhong et 
al., 2002). Thus, phosphorylation of RelA at several sites leads to recruitment of different 
coactivators, resulting in distinct patterns of gene expression (Chen and Greene, 2004). 
Directly increased transcriptional activity of RelA is also mediated by different serines, 
phosphorylated by various kinases, such as the mitogen- and stress-activated kinase-1 
(MSK1) or protein kinase A (PKAc) (Vermeulen et al., 2003; Zhong et al., 1997). In 
addition, acetylation of RelA occurs in vivo in response to TNFα or phorbol 12-myristate 
13-acetate (PMA) (Rahman et al., 2002). The RelA-IκBα complex is disintegrated by 
acetylation of RelA at lysine 221, resulting in increased RelA activity (Chen and Greene, 
2004). In conclusion, posttranslational modifications of NF-κB have a major impact on the 
intensity of the NF-κB response.  
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1.4.2 HIVEP1 - gene and protein      
Besides NF-κB family members, the κB motif can be recognized by the neuronal κB 
binding factor (NKBF) (Moerman et al., 1999), developing brain factors (DBF1/2) (Cauley 
and Verma 1994), the brain-specific enhancer binding transcription activator (BETA) 
(Korner et al., 1989) or the HIVEP family (Hicar et al., 2001).  
The HIVEP genes HIVEP1, HIVEP2 and HIVEP3 are characterized by one large exon of 
~5.5 kb and by relatively small and nonconserved exons, spread over a large DNA region 
at the 5’ end. The 3’ region is more conserved, concerning exon size, exon-intron 
boundaries and sequence, since all HIVEP genes harbour a 176 bp exon, encoding most 
of their C-terminal Zn finger pair (Hicar et al., 2001). Proteins encoded by the HIVEP gene 
family are large proteins, comprising four to five Zn fingers and two ZAS domains, in 
which a characteristic pair of C2H2 Zn fingers is linked to an acidic-rich and 
serine/threonine-rich region (Wu et al., 1996). HIVEP proteins share only up to ~30% 
sequence similarity, but distinct protein regions, such as two Zn finger pairs, a putative 
NLS and the 5’-flanking proline- and glutamine/aspartate-rich region, including the 
immediately downstream serine-rich sequence, are highly conserved (Hicar et al., 2001).              
The HIVEP1 (MBP1/PRDII-BF/ZNF40) gene is located on chromosome 6 (6p24), 
spanning ~152 kb and consisting of 9 exons (cf. chapter 4.2.2). The 6p24 locus has been 
shown to be associated with acute myeloid leukemia (AML) (Chen et al., 2000) and the 
schizophrenia susceptibility locus maps to chromosomal region 6p22-6p24 (Olavesen et 
al., 1997). However, no studies have observed the HIVEP1 expression regulation up to 
now. The full length mRNA size of HIVEP1 is 8891 bp (NM_002114.2) and was detected 
by northern blots in several cell lines, including human cervix carcinoma (HeLa) cells, 
human B cell lines (X50-7, BJA-B), T cell line Jurkat, human retinal cell line and human 
fibroblasts (GM0010) (Baldwin et al., 1990). The full length HIVEP1 protein has a 
predicted size of 298 kDa and harbours two sets of C2H2 Zn finger pairs, which are widely 
separated by 1630 amino acids. Another Zn finger (C2X13HC) is located between the two 
pairs of C2H2 Zn fingers and an acidic putative transcription activation domain was found 
to be located downstream from the C-terminal Zn finger set (Fan and Maniatis, 1990). A 
possible phosphorylation site, rich of serine and threonine residues, and a putative NLS 
are positioned in the N-terminal part of HIVEP1 (Baldwin et al., 1990).  
By electrophoretic mobility shift assays (EMSAs), recombinant HIVEP1 has been shown 
to bind NF-κB and related motifs within the enhancer element of human immunodeficiency 
virus type-1 (HIV-1) and promoter regions of immunoglobulin kappa (Igκ), major 
histocompatibility complex (MHC) class I, interleukin 2-receptor (IL-2R) and interferon-β 
(IFN-β) (Baldwin et al., 1990; Fan and Maniatis, 1990; Muchardt et al., 1992; Seeler et al., 
1994). Thereby, Fan and Maniatis (Fan and Maniatis, 1990) demonstrated that each set of 
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Zn fingers is able to bind to NF-kB motifs independently. Two alternative HIVEP1 splice 
products have been proposed with predicted protein sizes of 70 kDa and 200 kDa, lacking 
the first (exon 4) and second (exon 6) Zn finger pair respectively, while both splice 
products were not able to activate HIV-1 gene expression (Muchardt et al., 1992), in 
contrast to recombinant full length HIVEP1 in vitro (Seeler et al., 1994). Instead, the 70 
kDa alternative splice product of HIVEP1, designated gatekeeper of apoptosis activating 
proteins 1 (GAAP1), was found in vitro to increase the expression of interferon regulatory 
factor-1 (IRF-1) and p53 by binding to a novel regulatory element in their promoter 
regions, the IRF-1/p53 common sequence (IPCS) motif (Lallemand et al., 2002). An 
enhanced green fluorescent protein (eGFP)/GAAP1 fusion protein encoding plasmid was 
transfected into human hepatocarcinoma cells (HuH-7) and detected in both, the 
cytoplasm and nucleus. Notably, after deletion of a C-terminal PEST-like (i.e. rich in 
proline, glutamic acid, serine, threonine) sequence, GAAP1 was located exclusively in the 
nucleus (Lallemand et al., 2002). In this respect, Fan and Maniatis (Fan and Maniatis, 
1990) reported exclusive nuclear localization of HIVEP1 in osteosarcoma cells (MG63), 
using an antibody, that targets the C-terminal residue of HIVEP1. Another HIVEP1 
peptide, termed Cirhin interaction protein (Cirip), harbouring the C-terminal Zn finger pair 
and a NLS, was identified by yeast two-hybrid screening as well as coimmunoprecipitation 
to interact with the nucleolar protein Cirhin, which leads to increased Cirip action on the 
HIV-1 enhancer (Yu et al., 2009). Mutation in CIRH1A led to amino acid change in Cirhin 
causing North American Indian Childhood Cirrhosis (NAIC) and weakens its positive 
regulatory effect on Cirip activity (Yu et al., 2009).  
So far, studies investigating the DNA binding capacity of HIVEP1 were based on 
recombinant HIVEP1 and the cellular role of HIVEP1 in NF-κB signaling and 
proinflammatory or apoptotic processes is not well characterized.  
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1.5 Aim and design of the study 
Since we recently identified the HIVEP1 locus to be replicatively associated with VT, with 
at least two tagging SNPs, one positioned 90 kb upstream (rs169713) and one in exon 4 
(rs2228220) of the HIVEP1 gene (Morange et al., 2010; Germain et al., 2011), and 
HIVEP1 was suggested to regulate expression of genes involved in inflammatory 
processes by recognizing NF-κB motifs, the aim of the current thesis was to characterize 
the regulation of HIVEP1 expression in a broader context, especially with respect to 
inflammatory conditions. As knowledge on HIVEP1 gene regulation is rather scarce to 
date, we attempted to analyze the gene expression regulation of HIVEP1 in endothelial 
and monocytic cells under basic and inflammatory conditions by semiquantitative PCR. 
Since statins harbour antiinflammatory properties, most likely via NF-κB singaling, we 
subsequently tested the potential impact of different clinically used statins on HIVEP1 
expression in endothelial cells under basic and inflammatory conditions. After 
investigation of the influence of inflammatory cytokines or statins on HIVEP1 mRNA 
expression, we analyzed the observed effects at the protein level using western blot. 
Since functionally active HIVEP1 promoter regions and potential transcriptional regulators 
have not been yet characterized, we aimed at functionally analyzing the HIVEP1 promoter 
structure, including a potential enhancer region encompassing rs169713. We thus 
performed reporter gene assays in both, monocytic and endothelial cells, to identify a 
putative cell type-specific HIVEP1 promoter structure and function. In addition, we 
analyzed the 5'-flanking region of HIVEP1 with respect to genetic variants and molecular 
haplotypes (MolHaps) and analyzed their influence on transcriptional activities. 
Subsequently, we conducted in silico analyses for prediction of potential TFs binding to 
the identified HIVEP1 promoter or regulatory regions, to evaluate the impact of 
trans-acting factors on HIVEP1 expression regulation. To demonstrate a potential impact 
of predicted TFs on HIVEP1 promoter activity in vitro, we performed overexpression as 
well as EMSA analyses under stimulatory and basic conditions to identify differential 
binding patterns under distinct physiological conditions. Chromatin immunoprecipitation 
(ChIP) assays were performed to confirm binding of TFs to the HIVEP1 promoter region in 
vivo. 
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2 MATERIAL 
2.1 Chemicals 
Chemical Manufacturer 
Acrylamide-Bisacrylamide 30% (37, 5:1) (AA/BA) Merck, Darmstadt 
Acetylsalicylic acid Sigma-Aldrich, Steinheim 
Agar (Bacto) BD Bioscience, Heidelberg 
Agarose Biozym Scientific, Oldendorf 
Ammonium persulfate (APS) Sigma-Aldrich, Steinheim 
Atorvastatin Biomol, Hamburg 
Betaine Sigma-Aldrich, Steinheim 
Blocking reagent, EMSA Roche Diagnostics, Mannheim  
Boridic acid Roth, Karlsruhe 
Bromphenol blue Sigma-Aldrich, Steinheim 
Calcium chloride (CaCl2) Sigma-Aldrich, Steinheim 
Caseine Sigma-Aldrich, Steinheim 
Chloroform Fluka Reidel.de Haën, Seelze 
Coomassie Brilliant Blue R-250 Roth, Karlsruhe 
Cobalt(II) chloride (CoCl2) Merck, Darmstad 
Deoxycholic acid Sigma-Aldrich, Steinheim 
4',6-diamidino-2-phenylindole (DAPI) Sigma-Aldrich, Steinheim 
Dimethyl sulfoxide (DMSO) Merck, Darmstadt 
dNTPs (dATP, dCTP, dGTP, dTTP) Fermentas, St. Leon-Rot 
1,4 Dithiothreitol (DTT) Roth, Karlsruhe 
Ethanol Merck, Darmstadt 
Ethidium bromide Roth, Karlsruhe 
Ethylenediamine tetraacetic acid (EDTA) Merck, Darmstadt 
Ethyleneglycol-tetraacetic acid (EGTA) Merck, Darmstadt 
Ficoll Fluka Reidel.de Haën, Seelze 
Formaldehyde 37% Roth, Karlsruhe 
Gelatin Sigma-Aldrich, Steinheim 
Glacial acetic acid Roth, Karlsruhe 
L-Glutamine Sigma-Aldrich, Steinheim 
Glycerol Roth, Karlsruhe 
Glycine Roth, Karlsruhe 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) Roth, Karlsruhe 
Imidazole Roth, Karlsruhe 
Interleukin-1β (IL-1 β) Calbiochem, Darmstadt 
Isopropylalcohol Merck, Darmstadt 
Lithium chloride (LiCl) Merck, Darmstadt 
Magnesium chloride hexahydrate (MgCl2) Roth, Karlsruhe 
Manganese(II) chloride (MnCl2) Sigma-Aldrich, Steinheim 
β-Mercaptoethanol Serva, Heidelberg 
Methanol Roth, Karlsruhe 
3-(N-Morpholino)propanesulfonic acid (MOPS) Sigma-Aldrich, Steinheim 
N’,N’,N’,N’-Tetramethylendiamine (TEMED) Roth, Karlsruhe 
Nonidet P-40  Sigma-Aldrich, Steinheim 
Paraformaldehyde, powder (95%) (PFA) Sigma-Aldrich, Steinheim 
Phenylmethylsulphonyl fluoride (PMSF) Roth, Karlsruhe 
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Chemical Manufacturer 
Phorbol-12-myristate-13-acetate (PMA) Sigma-Aldrich, Steinheim 
Poly(dI•dC) USB, Staufen 
Potassium chloride (KCl) Merck, Darmstadt 
Pravastatin Sigma-Aldrich, Steinheim 
Protease inhibitor cocktail with EDTA (Complete) Roche Diagnostics, Mannheim 
Rosuvastatin Biomol, Hamburg 
Simvastatin Sigma-Aldrich, Steinheim 
Sodium acetate (NaAc) Merck, Darmstadt 
Sodium bicarbonate (NaHCO3) Sigma-Aldrich 
Sodium chloride (NaCl) Roth, Karlsruhe 
Sodium deoxycholate Simga-Aldrich 
Sodium dodecyl sulfate (SDS) Roth, Karlsruhe 
Sodium heparin Invitrogen, Karlsruhe 
Spermidine Fluka Riedel-de Haën 
Tumor necrosis factor α (TNFα) Cell Signaling, Frankfurt 
Tris-(hydroxymethyl)-aminomethane (Tris-base) Roth, Karlsruhe 
Triton X-100 Roth, Karlsruhe 
Tryptone (Bacto) BD Bioscience, Heidelberg 
Tween-20 Roth, Karlsruhe 
Biotin-16-ddUTP Roche Diagnostics, Mannheim 
Xylene xyanole Roth, Karlsruhe 
Yeast (Bacto) extract BD Bioscience, Heidelberg 
 
2.2 Sera and media 
Serum/medium Manufacturer 
Dulbecco’s modified eagle’s medium (DMEM) Sigma-Aldrich, Steinheim 
Dulbecco’s phosphate buffered saline (PBS) PAA, Pasching 
Fetal bovine serum (conditioned) (FBS)  PAA, Pasching 
Fetal calf serum (FCS), iron-supplemented  Cell Concepts, Umkirch 
Roswell Park Memorial Institute 1640 medium (RPMI) Sigma-Aldrich, Steinheim 
 
2.3 Consumables and kits 
Consumable/kit Manufacturer 
BCA Protein Assay Kit  Thermo Fischer, Bonn 
CL-X Posure Film Thermo Fischer, Bonn 
Gateway LR Clonase II Enzyme Mix Invitrogen, Karlsruhe 
High Pure PCR Product Purification Kit  Roche Diagnostics, Mannheim 
KAPA-HiFi PCR Kit PEQLAB, Erlangen  
Immobilon-P Transfer Membrane (PVDF) Millipore, Bedford, USA 
LightShift Chemiluminescent EMSA Detection Kit Thermo Fischer, Bonn 
LR Clonase II Enzyme Mix Invitrogen, Karlsruhe 
Luciferase Assay System Promega, Mannheim 
Magnetic Protein-G beads   Invitrogen, Karlsruhe 
M-MuLV Reverse Transcriptase Fermentas, St. Leon-Rot 
Nanofectin PAA, Pasching 
NucleoSpin Plasmid   Macherey-Nagel, Düren 
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Consumable/kit Manufacturer 
NucleoSpin RNA II Macherey-Nagel, Düren 
Oligofectamine Invitrogen, Karlsruhe 
Passive Lysis Buffer (5 x) Promega, Mannheim 
pCR8/GW/TOPO TA Cloning Invitrogen, Karlsruhe 
PureLink HiPure Plasmid DNA Purification Kit Invitrogen, Karlsruhe 
QIAamp DNA Blood Mini Kit   Qiagen, Hilden 
QIAquick Gel Extraction Kit Qiagen, Hilden 
siRNA duplex Ambion, Carlsbad, USA 
siRNA control duplex (low GC) Invitrogen, Karlsruhe 
SuperScript III Reverse Transcriptase Invitrogen, Karlsruhe 
SuperSignal West Chemiluminescent Substrate 
Pico/Femto Thermo Fischer, Bonn 
tRNA Roche Diagnostics, Mannheim 
Whatman Paper 3MM Chr.   Biometra, Göttingen 
Pipette tips 0.1 μl - 1000 μl Sarstedt, Nürnbrecht 
Reaction tubes 0.2 ml - 2 ml    Eppendorf, Hamburg Biozym, Hess. Oldendorf 
15 ml/50 ml tubes Greiner, Kremsmünster Nunc, Wiesbaden 
Petri dishes    Sarstedt, Nürnbrecht 
Plastics for cell culture Greiner, Kremsmünster 
PCR plates, microtiter plates Abgene, Hamburg 
 
2.4 DNA and protein marker 
Marker Manufacturer 
GeneRuler 100 bp DNA ladder Fermentas, St. Leon-Rot 
GeneRuler 1 kb DNA ladder Fermentas, St. Leon-Rot 
Precision Plus Protein Dual Color Standard Plus BioRad, Munich 
Precision Plus Protein Western C BioRad, Munich 
      
2.5 Enzymes and antibiotics 
Enzyme/antibiotic Manufacturer 
Ampicillin Roth, Karlsruhe 
BigDye3.1 Applied Biosystems, Foster City, USA 
GoTaq DNA Polymerase Promega, Mannheim 
Penicillin/Streptomycin PAA, Pasching 
Proteinase K Fermentas, St. Leon-Rot 
Restriction endonucleases Fermentas, St. Leon-Rot 
RiboLock Fermentas, St. Leon-Rot 
Shrimp Alkaline Phosphatase Fermentas, St. Leon-Rot 
Spectinomycin Sigma-Aldrich, Steinheim 
TdT terminal transferase Roche Diagnostics, Mannheim 
Trypsine-EDTA (0.05%)   Gibco, Karlsruhe 
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2.6 Antibodies 
Antibody Host Manufacturer 
β-actin rabbit Cell Signaling, Frankfurt am Main 
EGR-1 rabbit Cell Signaling, Frankfurt am Main 
HIVEP1 mouse Abcam, Cambridge, UK 
SP1 rabbit Millipore, Bedford, USA 
WT1 mouse Millipore, Bedford, USA 
anti-mouse sheep GE Healthcare UK Ltd, Little Chalfont Buckinghamshire, UK 
anti-rabbit donkey GE Healthcare UK Ltd, Little Chalfont Buckinghamshire, UK 
anti-mouse,  
Cy3 -
conjugated 
donkey Millipore, Bedford, USA 
 
2.7 Plasmids and vectors 
Plasmid/vector Description Manufacturer/gift of 
pCR8/GW/TOPO cloning vector Invitrogen, Karlsruhe 
pGL3-Basic reporter gene vector Promega, Mannheim 
pGL3-Control reporter gene vector Promega, Mannheim 
pGL3-Promoter reporter gene vector Promega, Mannheim 
pRc/CMV expression vector Dr. Dimitris Kardassis, Heraklion, Greece 
pSP1/CMV expression vector Dr. Dimitris Kardassis, Heraklion, Greece 
pEGR1/CMV expression vector Dr. Dona Wong, Boston, USA 
pWT1(-/-)/CMV expression vector Dr. Kerstin Duning, Münster 
Bacterial aritifcal 
chromosome (BAC) 
RP11-456H18, 
AL157373.23 
contains the 5'-end of 
HIVEP1 and three CpG 
islands on chromosome 6 
BACPAC Resource Center, 
Oakland, USA 
 
 
2.8 Bacteria (E. coli) 
Strain Genotype Manufacturer 
Mach1 
derivatives of E.coli W strains 
ΔrecA1398 endA1 tonA Φ80ΔlacM15 
ΔlacX74 hsdR(rK- mK+) 
Invitrogen, Karlsruhe 
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2.9 Eucaryotic cells  
Line Origin Reference 
EA.hy926 Human vascular endothelium Edgell et al., 1983 
HEK293T Human embryonic kidney ATCC no.: CRL-11268 
HeLa Human cervix carcinoma DMSZ ACC57 
HEPG2 Human hepatocellular carcinoma ATCC no.: HB-8065 
HUVEC Human umbilical vein endothelium - 
Saos-2 Human osteosarcoma DSMZ no.: ACC 243 
THP1 Human monocytes ATCC no.: TIB-202 
U937 Human monocytes ATCC no.: CRL-1593.2 
 
2.10 Laboratory equipment 
Instrument Specification Manufacturer 
Autoclave FVS-2  Systec VX-75  
Fedegari, Albuzzano, Italy 
Systec, Wettenberg 
Cell counter Casy Model TT Innovatis, Bielefeld 
Centrifuge Multifuge 3SR Heraeus, Hanau 
Centrifuge 5415C Eppendorf, Hamburg 
Centrifuge 5417R Eppendorf, Hamburg 
Centrifuge 5810R Eppendorf, Hamburg 
Centrifuge J2-21M/E Beckman Coulter, Krefeld 
CO2-Incubator (eukaryotic cells) MCO-18AIC Sanyo, Munich 
Developing machine Optimax Protec, Oberstenfeld 
Gel electrophoresis chamber Mini PROTEAN BioRad, Munich 
Gel electrophoresis chamber StarPhoresis Starlab, Ahrensburg 
Gel imaging AlphaImagerEC Alpha Innotech Corp, San Leandro, USA 
Incubator shaker (bacteria) Shaker Series 25 New Brunswick Scientific, Nürtingen 
Luminometer Sirius V12 Berthold Detection Systems, Pforzheim 
Microbiological incubator B 6120 Heraeus, Hanau 
Microscope Axiovert 40 CFL Zeiss, Jena 
Microscope Axioplan 2 Zeiss, Jena 
pH-Meter Calimatic 766 Knick, Dülmen 
Power supply PowerPackBasic BioRad, Munich 
Spectrophotometer Nanophotometer Implen, Munich 
Sequence detection system 7500 ABIprism Applied Biosystems, Foster City, USA 
Sonicator Bioruptor UCD-200 Diagenode, Liège, Belgium
Sterile hood (bacteria) Class II type EF Clean air Techniek B.V., Woerden, The Netherlands
Sterile hood (eukaryotic cells) HS 12 Heraeus, Hanau 
Tank Blot chamber Mini Trans-Blot Cell BioRad, Munich 
Thermocycler PTC-225,  DNA Engine Tetrad (2) 
MJ Research, Miami, 
USA 
UV-table Transilluminator Intas, Göttingen 
Waterbath  GFL 1083 GFL, Großburgwedel 
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3 METHODS  
3.1 Molecular biological methods 
Standard molecular methods were performed as described in “Molecular Cloning” 
(Sambrook and Russel, 2001) or in manufacturers’ instructions. Modifications in protocols 
are indicated where appropriate. 
 
3.1.1 Isolation of nucleic acids 
3.1.1.1 Preparation of genomic DNA 
Genomic DNA from white blood cells was extracted using the QIAamp DNA Blood Kit 
(Qiagen). EDTA-treated human whole blood (200 µL) was mixed with 20 µL proteinase K 
and 200 µL binding buffer, incubated at 56°C for 10 min, and loaded onto the spin 
columns, allowing the DNA to bind to the silica-gel membrane. The DNA was eluted after 
two washing steps in dH2O (pH 7 - 8.5) or TE buffer and held at 4°C or stored at -20°C. 
 
3.1.1.2 Preparation of total RNA 
Total RNA was extracted from ~5 x 106 cultured cells using the NucleoSpin RNA II Kit 
(Macherey-Nagel) according to manufacturers’ protocol. Cells were lysed with 350 µL lysis 
buffer (1% β-mercaptoethanol). Subsequent clearance of the lysate was conducted by 
filtration through a filter column. Optimal binding conditions were achieved by addition of 
350 µL ethanol. The lysate was loaded onto the RNA binding column, the membrane 
desalted and DNA digested by addition of DNase for 15 min. After three washing steps, 
RNA was eluted in RNase-free water and stored at -80°C.   
 
3.1.1.3 Preparation of plasmid DNA 
The NucleoSpin Plasmid Kit (Macherey-Nagel) was used for preparation of plasmid DNA 
from E. coli cultures (2 mL). Cells were spun down and the pellet lysed for 5 min at RT. 
Neutralization buffer was added, followed by a centrifugation step to clear the lysate. DNA 
was loaded and bound to silica membrane. After washing twice, plasmid DNA was eluted 
and held at 4°C or stored at -20°C.  
Isolation of transfection grade endotoxin-free plasmid DNA from E. coli cultures was 
performed using the PureLink HiPure Plasmid DNA Purification Kit (Invitrogen) as 
described in manufacturers’ protocol. Cells from an overnight culture (100 mL) were spun 
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down and the pellet was resuspended in a RNase A containing buffer. After addition of 
lysis buffer for 5 min, lysate was cleared using precipitation buffer and centrifugation 
(12000 x g, 10 min, room temperature [RT]). The supernatant was cleared from bacterial 
endotoxins by additional incubation with Endotoxin Removal Buffer A and washing with 
Endotoxin Removal Buffer B. The cleared lysate were loaded onto a pre-equilibrated 
column, washed and eluted. DNA was precipitated by addition of isopropanol (70% v/v) 
and centrifugation (15000 x g, 30 min, 4°C). After washing with ethanol (70% v/v), DNA 
was air-dried and resuspended in TE buffer. Plasmid DNA was held at 4°C and stored at 
-20°C. In case of bacterial artificial chromosome (BAC) clone RP11-456H18, preparation 
was performed as described above except of addition of 1% NaCl to the washing buffer.    
 
Endotoxin Removal Buffer A         Endotoxin Removal Buffer B 
50 mM MOPS, pH 7.0    100 mM sodium acetate, pH 5.0 
750 mM sodium chloride    750 mM sodium chloride 
10% (w/v) Triton X-100    1% (w/v) Triton X-100 
10% (v/v) isopropyl alcohol 
 
 
3.1.2 Photometric measurement of nucleic acid concentration 
Measurement of concentration and purity of nucleic acids were performed photometrically 
using a nanophotometer (Implen). The particular elution buffer served as blank. An optical 
density (OD) of 1 at 260 nm indicates a concentration of 50 µg/mL of DNA or 40 µg/mL of 
RNA. The purity was indicated by the E260/E280 ratio (1.9 pure DNA, >2.0 pure RNA).  
 
3.1.3 Polymerase Chain Reaction (PCR) 
The PCR is conducted to amplify DNA fragments in vitro with two specific oligonucleotides 
(primer) using a thermo resistant DNA polymerase as described by Mullis et al. (Mullis et 
al., 1986). GoTaq DNA polymerase (Promega) was used for standard PCRs. A 
proofreading enzyme was used (KAPAHiFi, PeqLab) to assure amplicon sequence 
identity to template DNA for cloning of transfection vectors.    
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Standard PCR reaction   Standard PCR program 
5 ng of genomic DNA    Initial denaturation  95°C, 5 min 
10 μM sense primer (SS)   Denaturation   95°C, 1 min 
10 μM antisense primer (AS)   Annealing*  x°C, 45 sec           25-38  
200 μM of each dNTP   Elongation  72°C, 1 min/kb     cycles 
1 M betaine     Terminal elongation 72°C, 10 min 
1x DNA polymerase buffer   
0.6 U DNA polymerase     
add nuclease-free H2O to 25 μL  
        
*Annealing temperature (TA) depended on primer melting temperature (TM) and was 
calculated as ([TM(SS) + TM(AS)]/2) – 2 = TA.  
TM was calculated using the following algorithm (Nakano et al., 1999): 
TM= (wA+xT)*2 + (yG+zC)*4 - 16.6*log10(0.050) + 16.6*log10([Na+])  
(w,x,y,z are the number of the bases A,T,G,C in the sequence, respectively) 
 
Two modifications were applied where necessary: 
a) Touch down PCR 
For enrichment of specific PCR products annealing temperature is gradually decreased, 
starting at 5-10°C over calculated primer annealing temperature. Annealing temperature 
was reduced by 2°C every second cycle until the calculated annealing temperature was 
reached, followed by 25 cycles at final annealing temperature.  
 
b) Nested PCR 
For generation of a higher amount and specificity of a weak PCR signal. Amplified PCR 
products from the first run were used as templates for a second run using a second set of 
primers located within the first amplicon. PCR products from the first run were extracted 
from agarose gels (cf. chapter 3.1.6) or directly used as templates.  
 
3.1.4 Generation of cDNA 
Synthesis of cDNA was performed using Superscript III (Invitrogen) or M-MuLV Reverse 
Transcriptase (Fermentas) according to manufacturers’ instructions. Total RNA (0.5-1 µg) 
was mixed with 1 µL oligo(dT18-20), 1-2 µL dNTPs (10 mM each), 20-40 U RNase Inhibitor 
(RiboLock, Fermentas; RNaseOUT, Invitrogen) and the particular reverse transcriptase. 
RNA was reversely transcribed into cDNA at 50°C (Superscript III) or at 37°C (M-MuLV) 
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for 60 min. Reaction was inactivated at 70°C for 15 min (Superscript III) or for 10 min (M-
MuLV). Success of synthesis was routinely controlled by diagnostic PCR for human 
Ribosomal Protein 27 (RP27). To detect endogenous expression of HIVEP1, cDNA was 
used as template for amplification with specific primers (appendix, Table A1) in a 
semiquantitative PCR. 
 
3.1.5 DNA-modifying reactions 
3.1.5.1 Restriction of DNA 
DNA (100-500 ng) was restricted using 1 U of the appropriate endonuclease. dH2O and 
10 x reaction buffer were added to a total volume of 20 μl, incubated for 1h at 37°C. 
Restriction enzyme was heat-inactivated at 70°C for 10 min. Restriction of DNA was 
checked by agarose gel electrophoresis (cf. chapter 3.1.6).  
 
3.1.5.2 Dephosphorylation  
Shrimp Alkaline Phosphatase (SAP) was used for dephosphorylation of 5’-ends to avoid 
religation of linearized plasmid DNA. Digestion reaction was mixed with 1 U SAP and 10 x 
reaction buffer. dH2O was added to a total volume of 25 µL. Reaction mixture was 
incubated at 37°C for 30 min and heat-inactivated at 65°C for 10 min.   
 
3.1.5.3 Labeling and annealing of single-stranded oligonucleotides 
Single-stranded oligonucleotides (25-50 bp) for EMSA experiments were synthesized at a 
minimum coupling efficiency of >98.5% and purified twice by high pressure liquid 
chromatography (HPLC) (IBA, Göttingen). These oligonucleotides as well as 
double-stranded PCR products, were 3’-biotinylated with biotin-16-ddUTP (Roche) using 
TdT. In a reaction mix, containing 2 mM CoCl2, 500 pmol biotin-16-ddUTP and 60 U TdT, 
5 pmol of each probe were labeled at 37°C for 30 min. To remove excessive biotin 
molecules, labeled probes were chloroform-extracted and centrifuged twice (14000 x g, 2 
min, RT). Oligonucleotides were labeled prior to annealing, since double-stranded blunt or 
recessed 3’ termini are poor substrates for TdT. Taq polymerase (Promega) adds a 
protruding adenosine to the 3’ end and was therefore used for PCR products. Annealing 
of oligonucleotides (20 fmol) was achieved by denaturation at 95°C for 10 min in 100 mM 
NaCl and a subsequent slow cool down over night to RT. Double-stranded unlabeled 
probes (competitors) were generated using 2 pmol of each unlabeled oligonucleotide. 
Annealing was controlled routinely by gel electrophoresis. 
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3.1.6 Agarose gel electrophoresis  
Since DNA is negatively charged due to its phosphate backbone, DNA migrates in an 
electric field. Agarose concentrations of 0.8% to 2%, depending on fragment size, were 
applied in 1 x TAE buffer. Ethidium bromide was added to the gel solution at a 
concentration of 0.05 μg/mL to visualize DNA double-strands using the AlphaImager 
(Alpha Innotech Corporation) gel documentation system. 
 
50 x TAE buffer    6 x loading buffer 
40 mM Tris base    0.02% (w/v) bromphenole blue 
1 mM EDTA     0.02% (w/v) xylene xyanole 
5.71% glacial acetic acid    30% (v/v) glycerol 
      20 mM Tris-HCl, pH 7.6 
      2 mM EDTA  
 
3.1.7 Purification of PCR products 
Purification of DNA fragments for subsequent applications like sequencing or cloning was 
performed either by column wash, gel extraction or enzymatic reaction. 
 
3.1.7.1 Column purification 
Purification of PCR products was performed using the High Pure PCR Product Purification 
Kit (Roche). PCR reactions were mixed with binding buffer, loaded onto the silica 
membrane column and washed twice. DNA was eluted in 10 mM Tris-HCl (pH 8.5).   
 
3.1.7.2 Gel extraction 
Gel extraction was performed using the QIAquick Gel Extraction Kit (Qiagen). After 
resection from 0.8% agarose gels, DNA fragments were mixed with solubilization buffer 
QG (pH 7.5) and heated at 50°C for 10 min for dissolving of gel slices. Probes were mixed 
with one gel volume of isopropanol (100%) and loaded onto the silica membrane column. 
After two washing steps, DNA was eluted in buffer EB (10 mM Tris-HCl, pH 8.5).       
 
3.1.7.3 DNA precipitation  
Precipitation was performed to concentrate DNA in a sample. The sample was mixed with 
1/10 volume of 3 M NaAc (pH 5.2) and one volume isopropanol (100%), incubated at 
-80°C for 2h and centrifuged twice (maximal speed, 20 min, 4°C). After two washing steps 
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with ice-cold ethanol (70%), the pellet was air-dried and the DNA resuspended in ~20 µL 
nuclease-free dH2O.    
 
3.1.7.4 ExoSAP clean-up 
The ExoSAP-it protocol was used for rapid one-step PCR clean-up for sequencing 
reactions. A mixture of Exonuclease I (Exo) and Shrimp Alkaline Phosphatase (SAP) 
(both Fermentas) was used to digest small single-stranded fragments (e.g. primers) and 
to remove dNTPs. One µL of ExoSAP-it mixture was added to each PCR product (5 µL) 
and incubated at 37°C for 30 min. Inactivation of enzymes was performed at 80°C for 15 
min.  
 
ExoSAP mixture 
20 U Exonuclease I (E. coli) 
10 U Shrimp Alkaline Phosphatase (SAP) 
add dH2O to 100 µL 
 
3.1.8 Construction of reporter gene plasmids 
Promoter fragments were generated using DNA extracted from clone RP11-456H18, 
bearing HIVEP1 wild type (wt) sequence, or patients’ genomic DNA (MolProMD), bearing 
the respective variants, as template. Deletion constructs of the HIVEP1 5'-flanking region 
were amplified using one antisense primer at position +79 bp and sense primers (Table 2) 
generating constructs shown in Figure 7. Deletion constructs harbouring part of intron 1 
were generated with one antisense primer at position +421 and deletion constructs sense 
primers (Table 2). A 412 bp fragment comprising exon 1 and part of intron 1 was 
generated with sense primer at position +10 and the antisense primer at position +421 
(Table 2). The construct harbouring the rs169713 site was amplified using a sense primer 
at position -92387 (5'-CAGCTTTCACGTTCTCACCTG-3'), an antisense primer at position 
-92068 (5'-GCAGTGAGGTATGAGTGTGC-3') and genomic DNA, bearing the rs169713 C 
or T allele, as template. For all deletion constructs, genomic or BAC clone DNA 
representing the wt sequence was used as template. Each HIVEP1 MolHap construct 
(1-4) was generated using the primer set for deletion construct -1650/+79 and the 
genomic DNA of a patient, harbouring the respective MolHap sequence, as template.  
For transient transfection assays, synthesized PCR fragments were introduced in 
5'-3'-orientation into the promoter-less luciferase reporter gene vector pGL3-Basic 
(Promega, Figure 8) (deletion constructs) or into the pGL3-Promoter vector (Promega, 
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Figure 8) (enhancer constructs), harbouring the Simian vacuolating virus 40 (SV40) 
promoter for PIC assembly, using the Gateway cloning system (Invitrogen). The 
site-specific recombination property of bacteriophage λ is the basis of this cloning 
technique (Landy, 1989). Recombination occurs at attachment sequences of phage DNA 
(attP) and bacteria DNA (attB). Initially, the gel extracted PCR fragment was cloned into 
the entry vector pCR8/GW/TOPO. The introduced PCR fragment was flanked by attL 
sequences. The vector was subsequently transformed into competent Mach1 (Invitrogen) 
bacterial cells (cf. chapter 3.3.1.3) and the plasmid isolated and purified (cf. chapter 
3.1.1.3). The modified pGL3-Basic destination vector, bearing artificial attR sites, was 
mixed with the entry vector and incubated with the LR Clonase enzyme allowing the 
exchange of the Gateway cassette in combination with the insert of interest, e. g. the 
HIVEP1 promoter fragment. For verification of accurate insert size and orientation (5'-3'), 
plasmids were double digested with sequence-specific endonucleases (cf. chapter 
3.1.5.1) followed by agarose gel electrophoresis. Sequencing (cf. chapter 3.1.9) of 
generated plasmids for transfection assays was performed to guarantee sequence 
correctness and identity.  
 
Standard pCR8/GW/TOPO cloning reaction  LR clonase reaction 
1 µL salt solution (1.2 M NaCl, 0.06 M MgCl2)  100 ng entry vector 
1 µL pCR8/GW/TOPO cloning vector (10 ng/µL)  150 ng destination vector 
4 µL purified insert      2 µL LR Clonase 
incubation for 5 min at RT,     add TE buffer to 8 µL 
transformation in competent Mach1 bacterial cells  incubation for 1h at 25°C 
        add 1 µL Proteinase K 
        incubation for 10 min at 37°C 
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-2288
-1650
LUC-4790 +79/+421
-469
-1241
-1097
-740
LUC
LUC
LUC
LUC
LUC
LUC
+79/+421
+79/+421
+79/+421
+79/+421
+79/+421
+79/+421
Table 2: Oligonucleotide sequence for HIVEP1 promoter deletion constructs 
Description Sequence 5'-3' Position Ref. Accession # 
HIVEP1-4790 SS ACAGTTTGGTCAAGGTGCCA -4790 NC_000006.11 
HIVEP1-2288 SS GCATTATTTCATCGTAGGGTTAGC -2288 NC_000006.11 
HIVEP1-1650 SS  GGTCACACCTTGGTTCATGC -1650 NC_000006.11 
HIVEP1-1241 SS  CTGAGGAAACCCCCTTGGG -1241 NC_000006.11 
HIVEP1-1097 SS  ACTACGGCCCCGCCCGTC -1097 NC_000006.11 
HIVEP1-740 SS  CCCATCCAGTCCCTACACC -740 NC_000006.11 
HIVEP1-469 SS GCTAAACGTGCCCTACTCTGC -469 NC_000006.11 
HIVEP1+79 AS AACCTG CTGCCAGGACGCC +79 NC_000006.11 
HIVEP1+421 AS GGGAAAGAAACCCACAAAGC +421 NC_000006.11 
HIVEP1+10 SS GCCATCAGCAGCGCAGCTC +10 NC_000006.11 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Schematic representation of HIVEP1 promoter deletion constructs Deletion 
constructs were cloned into the pGL3 vector system (Promega). The pGL3-Basic vector contains a 
luciferase cassette adjacent to the multiple cloning site but lacks a promoter sequence. 
Transcriptionally active HIVEP1 promoter fragments result in the expression of the luciferase 
protein, permitting assessment of promoter activity in relative light units. Sequence positions are 
shown according to TSS. LUC: luciferase gene. 
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Figure 8: Schematic representation of the pGL3-Basic, pGL3-Promoter and pGL3-Control 
vector used in reporter gene assays The pGL3-Basic vector lacks eukaryotic promoter and 
enhancer sequences, the pGL3-Promoter vector contains a SV40 promoter upstream of the 
luciferase gene and the pGL3-Control vector possesses SV40 promoter and enhancer sequences. 
Putative promoter or enhancer sequences were introduced in 5'-3' orientation into the pGL3-Basic 
or pGL3-Promoter vector, respectively. MCS: Multiple cloning site. 
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3.1.9 Sequencing 
For detection and localization of genetic variants in the MolProMD study and to ascertain 
sequence accuracy of DNA fragments and plasmid constructs samples were sequenced 
(both strains) using an automated ABI 3730 fluorescence sequencer with BigDye 
terminator chemistry (PE Applied Biosystems). 
 
3.1.10 EMSA 
EMSA experiments were performed to analyze DNA/protein interactions in vitro. In a 
native Gel, DNA/protein complexes migrate through the gel according to their size and 
charge. Protein binding to the applied oligonucleotide (Table 3) is visualized as a “shifted” 
band, representing a larger, less mobile DNA/protein complex compared to the free 
migrating unbound oligonucleotides. 3'-biotinylated oligonucleotides were detected with an 
anti-biotin antibody. Per reaction, 5 µg nuclear protein extracts were incubated in binding 
buffer with 500 ng presheared poly dI●dC as non-specific competitor, 250 mM betaine 
and a 200-fold molar excess of unlabeled oligonucleotide as specific competitor for 5 min 
at RT. After addition of the labeled probe, reactions were incubated for 20 min at RT. 
Probes and complexes were separated on a 6% native PAGE (cf. chapter 3.2.3) (0.5 x 
TBE, 100 V), followed by blotting onto a PVDF membrane (cf. chapter 3.2.5) (0.5 x TBE, 
100 V, 60 min). Using UV-light (312 nm), DNA probes were cross-linked to the membrane 
for 15 min. Subsequently, the Chemiluminescent Nucleic Acid Detection Kit (Thermo 
Fischer) was used to visualize the blotted probes. Membranes were blocked, washed four 
times, equilibrated and incubated in substrate working solution (luminal/enhancer and 
peroxidase solution) followed by exposure to CL-X Posure Film (Thermo Fischer).  
 
4 x binding buffer   6% PAGE   5 x TBE 
20 mM MgCl2     2 mL AA/BA, 30%  45 mM Tris base 
240 mM KCl    1 mL 5 x TBE   45 mM boridic acid 
40 mM HEPES/KOH, pH 7.9  83.7 µL APS, 10%  10 mM EDTA 
5 mM spermidine   3.7 µL TEMED 
16% (w/v) Ficoll   add dH2O to 10 mL 
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Table 3: Oligonucleotide sequences of EMSA probes 
Description Sequence 5'-3' Position Reference 
HIVEP1 intron 1 
SS 
CGTCCTGGCAGCAGGTTCGGCGCGGGCTC
CGCGGCGGGGGCGCTGCAGCTGGGGAGGG
CGGCGGGGCGGAGGGGGGGGGGGGCAGG
AGCACATCCCTTCGGCGGGCGGGGGGCGT
GCGGGCGCGCGTGTGTGTGTGTG 
+63 NC_000006.11 
HIVEP1 intron 1 
AS 
CACACACACACACGCGCGCCCGCACGCCCC
CCGCCCGCCGAAGGGATGTGCTCCTGCCCC
CCCCCCCCTCCGCCCCGCCGCCCTCCCCAG
CTGCAGCGCCCCCGCCGCGGAGCCCGCGC
CGAACCTGCTGCCAGGACG 
+63 NC_000006.11 
HIVEP1 5'-
flanking region 
SS 
CTACACCCGGTCAGAGCTGGCGGCCGCGC
CGGCCCAGCTGGGCCCCGGCGCCTGGGCG
TCCCGCGCCCCTCGCCCCGGCCTCAACCCC
AGCCCCCGCGGGGACGCCCCCTCCCCCGC
CCACGCGTCGCCGCCCGCGGCCTCCCCTC
CTCCCGCCCCCGGGGATCCCCTGCCGCCC
CGCCCACCCGCGGGAAAGCCTCCGACCTTC
GCCCTGCCTCCCCCGCGCCGCCCGGCCCG
CGTTCCTCCCGCCGGCCCCAAAGACGCTAA
AC 
-728 NC_000006.11 
HIVEP1 5'-
flanking region 
AS 
GTTTAGCGTCTTTGGGGCCGGCGGGAGGAA
CGCGGGCCGGGCGGCGCGGGGGAGGCAG
GGCGAAGGTCGGAGGCTTTCCCGCGGGTG
GGCGGGGCGGCAGGGGATCCCCGGGGGC
GGGAGGAGGGGAGGCCGCGGGCGGCGAC
GCGTGGGCGGGGGAGGGGGCGTCCCCGC
GGGGGCTGGGGTTGAGGCCGGGGCGAGGG
GCGCGGGACGCCCAGGCGCCGGGGCCCAG
CTGGGCCGGCGCGGCCGCCAGCTCTGACC
GGGTGTAG 
-728 NC_000006.11 
NF-κB probe AB 
SS 
TTCACAATGACTTTCCCCTTCCTTCTACGCG
TTGCTGAGGAAACCCCCTTG -1275 NC_000006.11 
NF-κB probe AB 
AS 
CAAGGGGGTTTCCTCAGCAACGCGTAGAAG
GAAGGGGAAAGTCATTGTGAA -1275 NC_000006.11 
NF-κB probe A 
SS TTCACAATGACTTTCCCCTTCCTTCTACGC -1275 NC_000006.11 
NF-κB probe A 
AS AAGTGTTACTGAAAGGGGAAGGAAGATGCG -1275 NC_000006.11 
NF-κB probe B 
SS TACGCGTTGCTGAGGAAACCCCCTTG -1245 NC_000006.11 
NF-κB probe B 
AS ATGCGCAACGACTCCTTTGGGGGAAC -1245 NC_000006.11 
NF-κB 
consensus site 
AGTTGAGGGGACTTTCCCAGGC - Lenardo & Baltimore, 1989 
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3.1.11 ChIP Assay  
ChIP assays were performed to investigate the association of TF with the DNA of interest 
in vivo using a modified protocol (Boyd et al. 1998; Liu et al., 2000). The technique 
involves crosslinking of proteins with the DNA and precipitation of bound chromatin using 
selected specific antibodies. PCR was performed for identification of the DNA fragment 
associated with the protein. About 107 cells were fixed by addition of formaldehyde (final 
concentration 1%) for 20 min at RT. Fixation was stopped by addition of 140 µL/mL 
glycine (1 M) for 5 min at RT. Cells were washed twice with ice-cold PBS (Sigma) and 
lysed for 10 min at RT. After centrifugation, isolated nuclei were sonicated using a 
Bioruptor (Diagenode, intensity: high, interval: 0.5, 45 min) to result in an average 
chromatin length of ~500 bp. Size of chromatin fragments was routinely controlled using 
agarose gel electrophoresis. After centrifugation, the supernatant was incubated with 
rabbit pre-immune serum for 30 min at 4°C and subsequently incubated with freshly 
prepared magnetic Protein-G beads (blocked with BSA and tRNA 1h, 4°C) for 30 min at 
4°C. After centrifugation, supernatant was transferred to low-binding tubes and 4 µg of 
specific antibody against SP1 (Upstate), EGR1 (Cell Signaling) or WT1 (Millipore) was 
added and incubated over night at 4°C. The next day, samples were incubated with 
freshly prepared magnetic Protein-G beads for 3h at 4°C. After several washing steps 
using wash buffer I, II and III, the antibody/protein/DNA complex was eluted from the 
beads. Crosslinks were reversed at 67°C over night and protein digested using proteinase 
K (2h, 37°C). DNA was extracted by phenol/chloroform/isoamyl alcohol extraction, 
resuspended in nuclease-free dH2O and used for PCR analysis (oligonucleotide 
sequences in Table 4).  
 
Cellular lysis buffer  Nuclear lysis buffer  Dilution buffer 
10 mM Tris pH 8.0  50 mM Tris pH 8.0  20 mM Tris pH 8.0 
10 mM NaCl   10 mM EDTA   2 mM EDTA 
0.2% (v/v) NP-40  1% (w/v) SDS   150 mM NaCl 
Roche Complete  Roche Complete  1% (w/v) Triton X-100 
proteinase inhibitor  proteinase inhibitor  Roche Complete 
        proteinase inhibitor 
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Wash buffer I   Wash buffer II   Wash buffer III 
20 mM Tris pH 8.0  10 mM Tris pH 8.0  20 mM Tris pH 7.6 
2 mM EDTA   1 mM EDTA   50 mM NaCl 
50 mM NaCl   0.25 mM LiCl     
1% (w/v) Triton X-100 1% (v/v) NP-40     
0.1% (w/v) SDS  1% (w/v) Deoxycholic acid 
Roche Complete   
proteinase inhibitor 
 
Elution buffer 
10 mM NaHCO3 
1% (w/v) SDS 
 
Table 4: Oligonucleotide sequences for ChIP  
Description Sequence 5'-3' Position Ref. Accession # 
HIVEP1 ChIP -307 to -469 SS GCTAAACGTGCCCTACTCTGC -307 NC_000006.11 
HIVEP1 ChIP -307 to -469 AS GAGCCACGGCATGATCGC -469 NC_000006.11 
HIVEP1 ChIP -916 to -1097 SS ACTACGGCCCCGCCCGTC -916 NC_000006.11 
HIVEP1 ChIP -916 to -1097 AS GAGGGGCGGGGTTAGGGA -1097 NC_000006.11 
 
3.1.12 siRNA  
To knockdown HIVEP1, EA.hy926 cells were transfected with a siRNA duplex targeting 
HIVEP1 exon 8 using Oligofectamine (Invitrogen) according to manufacturers’ protocol. 
Knockdown efficiency was monitored by semiquantitative PCR. After analyzing the 
existence of HIVEP1 transcripts in EA.hy926 cells, HIVEP1 exon 8 was chosen as target 
for siRNA. The siRNA was designed using the siRNA selection program “siRNA at 
WHITEHEAD” (http://sirna.wi.mit.edu/; format: AA(N19)TT) as described by Pei and 
Tuschl (Pei and Tuschl, 2006). Off-target effects were additionally checked using the net-
based program “ParAlign” (http://www.paralign.org/). The most specific siRNA sequence 
targeting exon 8 (sense 5'-CGACACAAUUCCGUCUGUAUU-3'; antisense 
5'-UACAGACGGAAUUGUGUCGUU-3') was elected and synthesized by Ambion 
(Carlsbad, USA). For control of sequence-independent effects of siRNA transfection, a 
commercial control siRNA duplex (low GC, Invitrogen) was transfected, harbouring a low 
sequence homology to any known vertebrate transcript.  
3 Methods 
42 
 
A total of 4 x 105 cells/well were plated in 6-well plates one day prior transfection. The 
transfection reagent Oligofectamine (4 µL), 10 µL or 15 µL of HIVEP1 (20 µM) and control 
siRNA duplexes were diluted in DMEM. After incubation for 10 min at RT, diluted siRNA 
duplexes were mixed with diluted Oligofectamine and incubated for 20 min at RT. Cells 
were washed with DMEM and transfection complexes added dropwise to cells in DMEM. 
After 4h, 5% FCS containing DMEM was added and knockdown was analyzed after 48h. 
Cells were harvested, RNA isolated (cf. chapter 3.1.1.2), cDNA generated (cf. chapter 
3.1.4) and semiquantitative PCR performed (oligonucleotide sequences cf. appendix, 
Table A1), whereby RP27-PCR served as gel loading control.     
 
 
3.2 Protein biochemical methods 
3.2.1 Extraction of proteins 
3.2.1.1 Preparation of cellular protein extracts 
Cells were harvested by scraping in lysis buffer to prepare crude proteins. To remove 
cellular debris, samples were centrifuged (12000 x g, 5 min, 4°C). Supernatants were 
mixed with pre-heated 4 x SDS-PAGE sample buffer and heated to 95°C for 5 min. 
Protein samples were aliquoted and stored at -70°C.  
 
Lysis buffer     4 x SDS sample buffer 
150 mM sodium chloride  200 mM Tris-HCl, pH 6.8 
1% Triton X-100   8% (w/v) SDS 
0.5% sodium deoxycholate  0.4% (w/v) bromphenol blue 
0.1% SDS    40% (v/v) glycerol 
50 mM Tris, pH 8.0 
 
3.2.1.2 Preparation of nuclear proteins 
Nuclear protein extracts were prepared by a modified protocol by Schreiber et al. 
(Schreiber at al., 1989). A total of 107 cells were washed twice with ice-cold PBS, scraped 
and centrifuged (5000 x g, 2 min, 4°C). Pellets were resuspended in a low salt buffer 
(500-800 µL) and allowed to swell for 15 min on ice. After addition of 25-75 µL NP-40 
(10% solution) and incubation for 5 min at RT, lysed cells were centrifuged (5000 x g, 5 
min, 4°C). The supernatant containing the cytosolic protein was removed and stored at 
-80°C, while pellets were resuspended in a high salt buffer (50-150 µL). After 3h of 
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incubation, cellular debris was spun down twice (24000 x g, 1h, 4°C) and the nuclear 
protein extracts were aliquoted on ice, snap frozen in liquid nitrogen and stored at -80°C. 
 
Low salt buffer     High salt buffer 
10 mM HEPES, pH 7.9    20 mM HEPES, pH 7.9   
10 mM KCl      0.2 mM EDTA pH 8.0 
1 mM DTT      1 mM DTT 
1.5 mM MgCl2      420 mM NaCl 
Roche Complete proteinase inhibitor  1.5 mM MgCl2 
       0.5 mM PMSF 
       25% (v/v) glycerol 
       Roche Complete proteinase inhibitor 
 
3.2.2 Protein quantification 
Quantification of the protein content was measured by usage of the BCA Protein Assays 
Kit (Thermo Fischer). The measurement of a series of dilutions with known concentrations 
of BSA served as standard curve. Concentrations of proteins were determined 
photometrically and calculated with reference to the standard curve.  
 
3.2.3 SDS-Polyacrylamide Gel Electrophoresis (PAGE) 
A 10% SDS gel was used for separation of protein samples as described by Rittenhouse 
and Marcus (Rittenhouse and Marcus, 1984). The anionic detergent SDS leads to the 
negative charge of the protein in relation to its mass, thus the migration distance of the 
protein in the gel is assumed to be directly proportional the protein size. Denaturation of 
proteins was achieved by incubation of protein samples in SDS sample buffer at 95°C for 
10 min. After incubation on ice for 5 min, samples ran on a stacking gel (4% 
polyacrylamide) at 80 V and were separated in the following 10% gel at 100 V. Running 
time depended on protein size and running of the gel was controlled using a prestained 
marker.   
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Stacking gel (4%)    Running gel (10%) 
560 µL AA/BA, 30%    2.5 mL AA/BA, 30% 
675 µL 0.5 M Tris-HCl, pH 6.8  1.9 mL 1.5 M Tris-HCl, pH 8.8 
675 µL 0.5 M imidazole, pH 6.8  75 µL SDS, 10% 
75 µL SDS, 10%    25 µL APS, 10% 
40 µL APS, 10%    5 µL TEMED 
5 µL TEMED     add dH2O to 7.5 mL 
add dH2O to 4.2 mL 
 
1 x SDS running buffer 
25 mM Tris base 
102 mM glycine 
1% (w/v) SDS 
 
 
3.2.4 Coomassie blue staining 
Visualization of protein bands was performed by incubation (1h) of the gel in Coomassie 
blue staining solution, followed by destaining.  
 
Coomassie staining solution     Destaining solution 
0.25% (w/v) Coomassie Brilliant Blue R-250  45% methanol 
45% (v/v) methanol      10% acetic acid 
10% (v/v) acetic acid      add dH2O 
add dH2O 
 
3.2.5 Western blot (tank blot) 
Proteins were blotted onto a PVDF membrane following the Towbin tank blot protocol 
(Towbin et al., 1979). After separation of proteins on a SDS gel (cf. chapter 3.2.3). A 
PVDF membrane was activated for 5 min in methanol and equilibrated in blotting buffer. 
The membrane was placed onto the gel and covered with two sheets of whatman-paper 
on each site. Blots were run for 1h at 100 V using cooling units. After blotting, membranes 
were saturated in blocking buffer at 4°C over night. Detection of proteins of interest was 
performed by immunodetection using a specific primary antibody for 1h at RT with 
following dilutions: anti-HIVEP1 (Abcam; mouse) 1:15000 and anti-β-actin (Cell Signaling; 
rabbit) 1:1000. Horseradish-peroxidase-coupled secondary antibodies (GE Healthcare UK 
Ltd) were given for 45 min (RT) at following dilutions: anti-mouse 1:100000 and anti-rabbit 
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of 1:5000. After extensive washing, membranes were incubated for 5 min in SuperSignal 
West Chemiluminescent Substrate (Pico or Femto, Thermo Scientific) and exposed to CL-
X Posure Film (Thermo Fischer). β-actin served as gel loading control.  
 
1 x Blotting buffer  Blocking solution   Washing solution (1 x TBS-T) 
25 mM Tris base  4% (w/v) casein  100 mM Tris base  
192 mM glycine  in 1 x TBS-T   1.5 mM NaCl 
10% methanol      0.03% (v/v) Tween-20 
 
3.3 Cell biological and microbiological methods 
3.3.1 Procaryotic cells 
3.3.1.1 Procaryotic cell culture and storage 
Bacteria were used for the generation and amplification of plasmid DNA. Cultivation of 
bacteria was performed at 37°C either in liquid medium (lysogeny broth [LB]) or on LB 
Agar plates. Antibiotics were applied for specific selection of transformed bacteria. Pellets 
of overnight cultures were resuspended in LB Medium with 15% glycerol and snap frozen 
in liquid nitrogen and stored at -70°C.   
 
LB Medium     LB Agar 
10 g Bactotryptone    15 g Bacto Agar in 1000 mL LB Medium  
10 g NaCl     add appropriate antibiotics     
5 g Yeast extract    after cool down to 56°C 
add dH2O to 1000 mL, pH 7.0 
Autoclave at 121°C for 120 min 
 
 
3.3.1.2 Generation of chemically competent cells 
Competent bacterial cells were generated according to a modified protocol by Hanahan 
(Hanahan, 1983) for preparation and transformation of E. coli cells. The transformation 
efficiency of generated competent cells was routinely controlled by transformation of the 
pUC19 vector. LB-Medium (200 mL) was inoculated with E. coli cells and grown at 37°C 
to an OD600 of 0.5. Cells were incubated for 20 min in an ice bath and harvested by 
centrifugation (4000 x g, 15 min, 4°C). The pellet was resuspended in MnCl2-transform 
buffer (10 mL) and incubated on ice for 10 min. After centrifugation (3000 x g, 10 min, 
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4°C), the pellet was resuspended in MnCl2-transform buffer (7.4 mL) and mixed gently, 
followed by dropwise addition of 560 µL DMSO. Aliquots of 100 µL were snap frozen in 
liquid nitrogen and stored at -80°C.   
 
MnCl2-transform buffer 
10 mM HEPES, pH 6.8 
15 mM CaCl2 
20 mM KCl 
55 mM MnCl2 
 
3.3.1.3 Transformation 
An aliquot of competent cells (100 µL) was thawed on ice, incubated with 50 ng of 
transforming DNA for 25 min on ice, heat-shocked at 42°C for 30 sec and briefly cooled 
down on ice for 1 min. After addition of pre-warmed LB-Medium (250 µL), cells were 
shook at 37°C for 45 min. Cells (100-150 µL) were plated onto antibiotic agar plates and 
incubated at 37°C over night.  
 
3.3.2 Eukaryotic cells 
3.3.2.1 Eukaryotic cell culture 
The human vascular endothelial cell line EA.hy926 and the human embryonic kidney cell 
line HEK293T were maintained in DMEM (Sigma) containing 10% (v/v) FBS (PAA), 100 
U/mL penicillin (PAA), 100 µg/mL streptomycin (PAA) and 2 mM/mL L-Glutamine (PAA). 
For cultivation of HEK293T iron-supplemented FCS was used (Cell Concepts). The 
human cervix carcinoma cell line HeLa, the human hepatocellular carcinoma cell line 
HEPG2 and the monocytic cell lines THP1 and U937 were maintained in RPMI 1640 
medium containing 10% (v/v) FBS, 100 U/ml penicillin, 100 μg/ml streptomycin and 2 
mM/mL L-Glutamine. For cultivation of THP1 and U937 monocytes 1 x modified Eagle’s 
medium amino acid solution (Sigma) was added. Differentiation of monocytes into 
macrophages was performed by stimulation with 10-8 PMA for 72h. The human umbilical 
vein endothelial cells HUVEC were maintained in DMEM containing 10% (v/v) FBS (PAA), 
1000 U/mL penicillin (PAA), 1000 µg/mL streptomycin (PAA), 1% sodium heparin (Sigma) 
and basic fibroblast growth factor (Invitrogen). For stimulation, cells were treated with 
TNFα (10 ng/mL, 6h or 24h; Cell Signaling), IL-1β (10 ng/mL, 24h; Calbiochem) or PMA 
(10-8 M, 24h or 72h; Sigma). Statins were applied in following concentrations for 24-30h: 
1.2 or 2.4 µM simvastatin (Sigma), 3, 9 or 18 µM atorvastatin (Biomol), 2, 5, 10, or 20 µM 
rosuvastatin (Biomol) and 1, 5, 10, or 15 µM pravastatin (Sigma). Incubation of cells with 
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aspirin, used as control experiment for statin-specificity, was performed using 10, 250, 
500, 1000 µM acetylsalicylic acid (Sigma) for 24h. THP1 and U937 cells were kept at a 
concentration of 0.5 to 1 x 106/mL. When state of confluence was reached, cells were 
detached from surface by trypsination and splitted at appropriate ratios for further 
cultivation. Cells were cultivated at least for 2 passages before used for experiments. The 
number of passages did not exceed 40 in any case. 
 
3.3.2.2 Storage 
For long term storage cells were washed twice with PBS, trypsinated, and transferred to 
fresh medium. After centrifugation, cells were placed on ice and resuspended in fetal calf 
serum mixed with DMSO 10% (v/v). Cells were stored at -80°C and transferred to liquid 
nitrogen the next day. Thawing of cells was performed as quickly as possible, in a 
waterbath at 37°C. Cells were washed with PBS to remove DMSO from the freezing 
medium and transferred into pre-warmed medium after centrifugation. 
 
3.3.2.3 Transient transfection  
EA.hy926 and THP1 cells were transfected using Nanofectin (PAA). Nanofectin consists 
of a positively charged polymer with DNA-binding capacity, which is embedded into a 
porous nanoparticle. In case of EA.hy926, 105 cells/well were plated in 24-well plates an 
transfected the next day. Two hours prior transfection medium was changed. THP1 cells 
(1.5 x 105 cells/well) were plated in 24-well plates immediately prior addition of 
transfection complexes. For both, EA.hy926 and THP1 cells, 1 μg DNA and 3.2 µl 
Nanofectin solution was used and diluted in 50 µL NaCl solution (150 mM) and incubated 
for 10 min at RT. The diluted Nanofectin particles were dropwisly added to the diluted 
DNA and gently vortexed. After incubation for 30 min at RT, the transfection complexes 
were dropwisly added to the cell medium. In case of EA.hy926, transfection medium was 
replaced by fresh medium after 3h. After 24h post transfection, cells were harvested with 
100 µL Passive Lysis buffer (Promega) and luciferase activity was determined using a 
Sirius single-tube luminometer (Berthold detection system). The cell lysate/luciferase 
substrate ratio was routinely 20 μl/75 μl. The pGL3-Control vector, in which transcription is 
driven by the competent SV40 viral promoter and additional enhancer, served as positive 
control. Promotor-less pGL3-Basic vector served as empty shuttle vector control. 
Transfection experiments were repeated at least three times, in triplicates for each 
plasmid. 
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3.3.2.4 Cotransfection 
For cotransfection experiments, overexpression of certain proteins, in this study of TFs 
SP1, EGR1 and WT1, were performed to analyze the possible effect on transcription of 
the cotransfected reporter gene. The expression vector and reporter gene plasmids were 
transfected in a 3:1 ratio.  
 
3.3.2.5 Immunofluorescence 
For the determination of the cellular localization of HIVEP1, immunofluorescence was 
performed. Eight chambers of a chamber slide were covered with 1% gelatin and 5 x 104 
EA.hy926 cells plated in each chamber two days prior antibody incubation. After two 
washing steps with PBS (+ 1% BSA), cells were fixed using PFA (4%) for 15 min at RT. 
Cells were washed three times (PBS + 1% BSA) and blocking was performed for 30 min 
at 37°C by addition of blocking buffer (PBS + 5% FBS), containing 0.1% saponin. Saponin 
was added to permeabilize the cell membrane. First antibody (HIVEP1, Abcam) was 
diluted in blocking buffer and applied at a final concentration of 5 µg/mL for 3h at RT. As a 
control, cells were incubated with the first antibody diluted in blocking buffer without 
saponin. Unspecific binding of the secondary antibody was controlled in a chamber, which 
was not incubated with the first antibody. After three washing steps with blocking solution, 
the secondary Cy3-conjugated anti-mouse antibody (Millipore) was diluted 1:100 and 
added for 1h at RT in the dark. Cell nuclei staining was performed using 0.25 µg/mL DAPI 
(Sigma) for 5 min at RT. Cells were washed three times with blocking buffer and covered 
with cover slides. Analysis of immunfluorescence was performed by microscopy (UV-light, 
blue and red channel). 
 
3.4 Study population 
The current investigation was based on the Münster Molecular Functional Profiling for 
Mechanism Detection (MolProMD) study. The Münster MolProMD Study is a prospective 
study of patients with CVD (myocardial infarction, essential hypertension, etc.) and 
families, aimed at studying molecular genetic mechanism of CVD. The study was 
approved by the ethics committee of the Medical Faculty, Westfälische Wilhelms-
University of Münster and written informed consent was obtained from all study subjects. 
Genomic DNA from patients of this study was used for the detection of existing genetic 
variants by sequencing as well as for subcloning and generating gene promoter reporter 
vectors (Dördelmann et al., 2008).  
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3.5 Computational analyses of putative TFBS 
Prediction of TFBS was performed by in silico analysis using PROMO 
(http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) and 
AliBaba2.1 (http://www.generegulation.com/pub/programs/alibaba2/index.html) (Grabe, 
2002; Messeguer et al., 2002). Settings of the used algorithms are available upon request. 
Both programs use information on binding sites of the eukaryotic TRANSFAC database 
(PROMO, TRANSFAC 8.3; AliBaba2.1, TRANSFAC 7.0)   
 
3.6 Statistical methods 
P-values were calculated using the scientific analysis and presentation computer program 
“Graph Pad Prism 4.0/5.0”. Significance was calculated by unpaired, two-tailed student’s 
t-test (C.I.95%). The significance levels were set at ***p<0.001, **p<0.01, and *p<0.05. 
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4 RESULTS 
4.1 Endogenous expression of HIVEP1  
Determination of cell lines that endogenously express the gene of interest, e.g. HIVEP1, is 
the first important step in promoter studies, since each cell line harbours a distinct 
composition of TFs to promote stimuli- and tissue-specific gene expression (cf. chapter 
1.3). HIVEP1 mRNA expression has been studied in several cell lines, including human 
cervix carcinoma cells (HeLa), human B and T cells and fibroblasts, using northern blots 
(Baldwin et al., 1990) (cf. chapter 1.4.2). In the current work, endogenous expression of 
HIVEP1 was analyzed using semiquantitative PCR in THP1 and U937 monocytes, 
vascular endothelial cells (EA.hy926), human embryonic kidney cells (HEK293T), HeLa 
and human osteosarcoma cells (Saos-2). The constitutively expressed human 
house-keeping gene ribosomal protein 27 (RP27) served as gel loading control. All 
analyzed cell lines showed moderate endogenous HIVEP1 expression under basic 
conditions pointing to an ubiquitous HIVEP1 expression (Figure 9).  
  
 
 
 
 
 
Figure 9: Endogenous expression of HIVEP1 All analyzed cells, including vascular endothelial 
cells (EA.hy926), THP1 and U937 monocytes, human embryonic kidney cells (HEK293T), human 
cervix carcinoma cells (HeLa) and human osteosarcoma cells (Saos-2), revealed endogenous 
HIVEP1 expression under basic conditions. Semiquantitative PCR based on generated cDNA and 
was performed using primers positioned in HIVEP1 exon 1 and 4. RP27 served as gel loading 
control.  
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4.1.1 Influence of proinflammatory stimuli on HIVEP1 mRNA expresssion 
Since HIVEP1 is suggested to bind to NF-κB consensus sites (cf. chapter 1.4.2), we 
studied the potential involvement of HIVEP1 in inflammatory signaling pathways by 
microarray database research. The effect of proinflammatory stimuli on HIVEP1 mRNA 
expression was subsequently analyzed in monocytes and endothelial cells, since 
recruitment of monocytes is a crucial step in the inflammatory response and endothelial 
“dysfunction” is involved in early stages of VD (cf. chapter 1.2).  
 
4.1.1.1 Microarray database search 
We investigated available microarray data 
(http://www.ncbi.nlm.nih.gov/geo/info/linking.html) with respect to altered HIVEP1 mRNA 
expression under treatment with pro- and antiinflammatory effectors. We included 
datasets, which indicated a ≥30% change in HIVEP1 mRNA expression.  
Table 5: Involvement of HIVEP1 in inflammatory pathways 
Cell type Effector HIVEP1 mRNA expression Reference 
HUVEC IL-1 ++ ↑ Mayer et al., 2004 
HUVEC TNFα ++ ↑ Viemann et al., 2006 
Monocytes NF-κB- and PI3K-inhibitor - ↓ Chan et al., 2008 
RASF IκB -- ↓ Zhang et al., 2004 
Microarray databases indicated HIVEP1 mRNA expression to be affected by inflammatory stimuli. 
In primary human umbilical vein endothelial cells (HUVEC), treatment with interleukin-1 (IL-1) and 
tumor necrosis factor α (TNFα) was shown to elicit increased HIVEP1 mRNA expression (++ ↑). 
Inhibition of the NF-κB and phosphoinositide 3-kinase (PI3K) pathway in monocytes decreased 
HIVEP1 expression (- ↓), as did inhibitor kappa B (IκB) in rheumatoid synovial fibroblasts (RASF)   
(-- ↓), harbouring high TNFα levels. ++: ≥40% positive change, --: ≥40% negative change, -: ≥30% 
negative change. 
Incubation of primary human endothelial cells with IL-1 or TNFα was shown to increase 
HIVEP1 expression (Table 5; Mayer et al., 2004; Viemann et al., 2006), while HIVEP1 
expression was downregulated by NF-κB- or phosphoinositide 3-kinase (PI3K)-inhibitors 
in monocytes (Chan et al., 2008). In addition, inhibition of NF-κB signaling by IκB in 
inflammatory rheumatoid synovial fibroblasts (RASF), which constitutively yield high TNFα 
levels, was shown to decrease HIVEP1 expression (Zhang et al., 2004).  
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4.1.1.2 Impact of TNFα, IL-1β and PMA on HIVEP1 mRNA expression 
To evaluate the potential contribution of HIVEP1 as a mediator of inflammatory processes 
in onset and progression of VD, we examined the impact of cytokines TNFα and IL-1β on 
HIVEP1 expression in the well characterized vascular endothelial cells EA.hy926 and 
THP1 monocytes. THP1 monocytes were differentiated into macrophages by PMA.  
Incubation with TNFα resulted in increased HIVEP1 expression of both cell lines. IL-1β 
was a potent activator of endogenous HIVEP1 expression in EA.hy926 cells (Figure 10). 
Differentiation of THP1 monocytes to macrophages using PMA led to an increased 
HIVEP1 expression.   
 
 
 
 
 
 
Figure 10: Proinflammatory cytokines increased HIVEP1 expression in endothelial cells and 
monocytes Stimulation of EA.hy926 cells with TNFα or IL-1β led to an increase of HIVEP1 
expression. TNFα-incubated THP1 cells as well as differentiated macrophages displayed an 
increase of HIVEP1 expression. Cells were stimulated with TNFα (10 ng/mL, 24h), IL-1β (10 
ng/mL, 24h) or PMA (10-8 M, 72h) and total RNA was isolated for cDNA synthesis. RP27 served as 
loading control. Ø: basic conditions. 
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4.1.2 Effect of statins on HIVEP1 mRNA expression 
One of the major pleiotropic effects of statins is the antiinflammatory property (cf. chapter 
1.2.5). In this respect, Dichtl et al. (Dichtl et al., 2003) demonstrated that statins are able 
to reduce the binding affinity of NF-κB to its consensus site in endothelial cells with 
subsequently altered NF-κB target gene expression. To analyze a potential effect of 
statins on HIVEP1 expression, we examined the impact of clinically used statins on 
HIVEP1 expression in endothelial cells.  
Treatment of EA.hy926 cells with simvastatin led to a dose-dependent reduction of 
HIVEP1 expression. Endogenous HIVEP1 expression was abrogated by incubation with 
2.4 µM simvastatin (Figure 11A). Simvastatin was able to compensate the 
counterregulating TNFα-effect resulting in decreased HIVEP1 expression in TNFα-treated 
EA.hy926 cells (Figure 11A). Equal amounts of atorvastatin (3 µM) did not alter HIVEP1 
expression, while atorvastatin doses of up to 18 µM led to a decrease of HIVEP1 
expression below the basal expression level (mock) (Figure 11B). In TNFα-treated 
EA.hy926 cells, 9 µM atorvastatin resulted in decreased HIVEP1 expression, while we 
observed a paradoxic TNFα/statin effect resulting in increased HIVEP1 expression, when 
high-dose atorvastatin (18 µM) was used (Figure 11B). In addition the two lipophilic 
statins, simvastatin and atorvastatin, we incubated EA.hy926 cells with the hydrophilic 
statins rosuvastatin and pravastatin. Treatment of rosuvastatin with up to 20 µM led to a 
dose-dependent reduction of HIVEP1 expression (Figure 11C). Compensation of the 
TNFα-effect appeared at rosuvastatin doses of 10 and 20 µM, again dose-dependently 
(Figure 11C). Pravastatin instead was not able to alter HIVEP1 expression at any 
concentration in EA.hy926 cells (Figure 11D). The COX-1 inhibitor aspirin served as 
treatment control and did not influence HIVEP1 expression at all (Figure 11E), although 
we have shown that EA.hy926 cells express the TXA2 receptor, which is necessary for 
aspirin action (appendix, Figure A1).            
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Figure 11: Influence of statins on HIVEP1 expression in EA.hy926 cells A) Treatment of 
EA.hy926 cells with simvastatin (1.2 and 2.4 µM) resulted in a dose-dependent decrease of 
HIVEP1 expression. In TNFα-treated cells (10 ng/mL, 6h), simvastatin compensated the 
TNFα-effect, since HIVEP1 expression abrogated at a simvastatin concentration of 2.4 µM.          
B) Atrovastatin at a concentration of up to 18 µM led to decreased HIVEP1 expression. In the 
presence of TNFα, low-dose atrovastatin (9 µM) still downregulated HIVEP1 expression, while 
high-dose atorvastatin (18 µM) increased HIVEP1 expression. Atorvastatin at a concentration of 3 
µM had no effect on HIVEP1 expression. C) Application of rosuvastatin (2, 5, 10 and 20 µM) 
dose-dependently decreased HIVEP1 expression. In TNFα-treated cells, high-dose rosuvastatin 
(10 µM) was able to compensate the TNFα-effect resulting in a reduction of HIVEP1 expression. 
D/E) Neither concentration of pravastatin nor aspirin altered HIVEP1 expression. EA.hy926 cells 
were incubated with statins for 24h, subsequently RNA was isolated and cDNA generated. RP27 
served as loading control.    
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4.1.3 Influence of proinflammatory stimuli and statins on HIVEP1 protein 
expression   
To confirm that proinflammatory cytokines such as TNFα and statins affect HIVEP1 
expression also at the protein level, we performed western blot analysis using an antibody 
generated against the C-terminal residue of HIVEP1. In addition, we analyzed the 
increased HIVEP1 gene expression in macrophages compared to monocytes at the 
protein level.  
We identified a ~55 kDa HIVEP1 isoform in the nuclear fractions of THP1 monocytes and 
EA.hy926 cells, as well as in U937 monocytes, HUVEC, HEK293T, human hepatocellular 
carcinoma (HEPG2) and HeLa cells. By contrast, we could not detect HIVEP1 in the 
cytoplasm of any above mentioned cells (Figure 12). While we identified a strong signal 
for HIVEP1 in nuclear extracts of EA.hy926, HeLa and HEK293T cells, the signal was 
relatively low in THP1 nuclear extracts under basic conditions (Figure 12).   
 
 
 
Figure 12: Nuclear localization of HIVEP1 in different cell lines Western blot analysis revealed 
HIVEP1 protein expression in nuclear extracts. HIVEP1 was absent in the cytoplasm of THP1 and 
U937 monocytes, as well as in human cervix carcinoma (HeLa), vascular endothelial (EA.hy926), 
human embryonic kidney (HEK293T), human hepatocellular carcinoma (HEPG2) and human 
umbilical vein endothelial (HUVEC) cells. HIVEP1 was weakly expressed in THP1 monocytes and 
we observed elevated amounts of HIVEP1 in EA.hy926, HeLa and HEK293T nuclear extracts.      
c: cytoplasmic, n: nuclear. 
 
In our western blot analysis, β-actin served as loading control for comparison of the 
effects of proinflammatory stimuli or statins on HIVEP1 protein expression. All of the 
analyzed signals in nuclear extracts were comparable, since similar amounts of β-actin 
were detected in nuclear extracts (Figure 13A/B). 
Incubation of THP1 cells with TNFα led to increased HIVEP1 protein expression as well 
as differentiation of monocytes to macrophages by PMA (Figure 13A), which validate the 
results obtained at the mRNA level. By contrast, HIVEP1 protein expression was not 
affected by TNFα incubation or treatment with different statins in nuclear extracts of 
EA.hy926 cells (Figure 13B). Treatment of TNFα-stimulated cells with different statins had 
no effect on HIVEP1 protein expression in EA.hy926 nuclear extracts neither (Figure 
13B).  
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Figure 13: Effect of TNFα stimulation and statins at the HIVEP1 protein level A) TNFα (10 
ng/mL, 24h) and PMA (10-8 M, 72h) stimulation increased HIVEP1 protein expression in nuclear 
extracts of THP1 monocytes. B) Incubation of EA.hy926 cells with TNFα (T; 10 ng/mL, 24h) did not 
alter HIVEP1 protein expression as did treatment with statins in the presence or absence of TNFα. 
Before preparation of EA.hy926 nuclear extracts, the cells were incubated with statins (simvastatin, 
S, 2.4 µM; atorvastatin, A, 18 µM; pravastatin, P, 15 µM) for 30h and TNFα (10 ng/mL) was added 
after 24h for 6h. β-actin served as loading control. c: cytoplasmic, n: nuclear, Ø: basic conditions. 
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4.1.4 Determination of the cellular localization of endogenous HIVEP1 by 
immunofluorescence  
The HIVEP1 isoform GAAP1 was found in both, the cytoplasm and nucleus of HuH-7 
cells, while exclusive nuclear localization of recombinant GAAP1 was demonstrated after 
deletion of a PEST-like sequence (Lallemand et al., 2002). Using an antibody against the 
C-terminal HIVEP1 residue, Fan and Maniatis (Fan and Maniatis, 1990) detected nuclear 
localization of recombinant HIVEP1 in MG63 cells. In that respect, we analyzed the 
cellular localization of endogenous HIVEP1 in EA.hy926 cells using immunofluorescence. 
Cells were fixed and incubated with an unlabeled first antibody against the C-terminal 
HIVEP1 residue and a Cy3-labeled (red channel) secondary antibody. Cell nuclei were 
labeled with DAPI (blue channel). Antibodies were diluted in PBS, containing 0.1% (w/v) 
saponin to permeabilize the cell membrane allowing detection of proteins in the nucleus. 
Antibodies diluted in PBS without saponin served as negative control 2, while negative 
control 1 was performed by incubation of cells with the secondary antibody without prior 
incubation with the primary antibody. 
Immunofluorescence of HIVEP1 revealed that endogenous HIVEP1 was located within 
the nuclei of EA.hy926 cells, while absent in the cytoplasm (Figure 14, merge). Negative 
controls 1 and 2 revealed that the secondary antibody did not bind unspecific and the 
primary antibody needed the detergent saponin to get into the nucleus of intact cells, 
respectively (Figure 14). 
 
 
 
 
 
 
 
 
 
Figure 14: Nuclear localization of HIVEP1 in EA.hy926 cells Immunofluorescence of HIVEP1 in 
EA.hy926 cells revealed localization of HIVEP1 in the nuclei of EA.hy926 cells. HIVEP1 was 
visualized with a specific primary antibody and a Cy3-conjugated secondary antibody (red 
channel). Nuclear staining was performed using DAPI (blue channel). Negative control 1 revealed 
no unspecific binding of the secondary antibody, while negative control 2 demonstrated the need of 
saponin to get the primary anti-HIVEP1 antibody into the nucleus of intact cells. Scale bar 50 µm.  
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4.2 Identification and functional analysis of genetic variants in the  
HIVEP1 5'-flanking region  
Since we recently identified a tagging SNP (rs169713T>C) positioned 90 kb upstream of 
the HIVEP1 gene to be replicatively associated with VT (Morange et al., 2010), we 
performed reporter gene assays to analyze the potential enhancer capacity of the region 
flanking rs169713 (cf. chapter 4.2.1). Dördelmann et al. as well as Hagedorn et al. 
(Dördelmann et al., 2008; Hagedorn et al., 2009) demonstrated the potential impact of 
SNPs and molecular haplotypes on gene expression regulation, therefore we screened 
the region 5 kb upstream of HIVEP1 with respect to genetic variants in CVD patients. 
Subsequently, we analyzed the impact of molecular haplotypes on HIVEP1 gene 
expression regulation in EA.hy926 and THP1 cells.      
 
4.2.1 Potential enhancer capacity of the rs169713 polymorphic site 
The analysis of the putative enhancer site was conducted by cloning a 319 bp fragment 
comprising either rs169713 C or T allele into the pGL3-Promoter vector upstream of the 
luciferase gene. The pGL3-Promoter vector contains the SV40 promoter for PIC 
assembly, but lacks an active enhancer. Transient transfection assays were performed in 
EA.hy926 and THP1 cells and transcriptional activities of reporter constructs were 
assessed as relative light units (RLU).  
In EA.hy926 cells, the construct containing the C allele displayed transcriptional activity at 
the level of the pGL3-Promoter shuttle vector (Figure 15A). Insertion of the T allele 
significantly increased transcriptional activity compared to the construct harbouring the C 
allele and the pGL3-Promoter vector (Figure 15A, both p<0.001), indicating a potential 
enhancer function for the rs169713 T allel-carrying portion. We observed similar results in 
THP1 cells but with smaller effects. The construct comprising the T allele displayed the 
strongest transcriptional activity compared to the C allele and the pGL3-Promoter vector 
(Figure 15B).   
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Figure 15: Enhancer capacity of a 90 kb upstream region harbouring the rs169713 T allele  
A) The construct containing the T allele had a significant higher transcriptional activity compared to 
the C allele-carrying construct and the pGL3-Promoter vector in EA.hy926 cells (both p<0.001).  
B) In THP1 cells, we observed the strongest transcriptional activity for the construct harbouring 
rs169713 T allele. White bars indicate transcriptional activity of the pGL3-Control, black bars of the 
pGL3-Promoter (Prom) vector. Transcriptional activity was assessed as relative light units (RLU). 
***p<0.001, **p<0.01, *p<0.05, ns = not significant.  
 
4.2.2 Identification of additional HIVEP1 promoter variants 
Screening of 5 kb of the HIVEP1 5'-flanking region in 57 patients with CVD (MolProMD 
study) revealed ten genetic variants (Figure 16, red and blue lines), while two of them 
were newly identified (blue lines). Positions of tagging SNPs rs169713 and rs2282220 as 
well as the HIVEP1 gene architecture are schematically shown in Figure 16. 
 
 
Figure 16: Genetic architecture of the HIVEP1 gene and positions of identified genetic 
variants The HIVEP1 gene maps to chromosome 6, spans 152 kb and consists of 9 exons 
(boxes). Black boxes represent the 5'- and 3'-untranslated regions. The TSS is indicated by an 
arrow and the translation start in exon 2 by an asterisk. Ten genetic variants (red and blue lines), 
two of which were novel (blue lines), were identified in 57 individuals of the MolProMD study. 
Tagging SNP rs169713 maps to the pseudogene LOC100129671 90 kb upstream of HIVEP1 and 
rs2282220 to HIVEP1 exon 4. 
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4.2.3 MolHap analysis 
We subsequently analyzed the identified genetic variants in the HIVEP1 5'-flanking region 
with respect to MolHaps formation. Three adjacent SNPs (rs1574343_A>T, 
rs1574166_C>G, rs3902984_A>C), located between positions -1060 to -953 relative to 
the TSS of HIVEP1, were identified by individual subcloning to constitute four MolHaps 
(MolHaps 1-4, Figure 17A). MolHap1 (A-1060-C-1037-A-953) represents the most frequent 
MolHap. We generated HIVEP1 MolHap promoter constructs by cloning a HIVEP1 
promoter fragment, comprising positions -1650 to +79, harbouring either one of the 
MolHap sequences into the pGL3-Basic vector. Transient transfection assays in EA.hy926 
cells revealed a moderate stepwise decrease of transcriptional activity by introducing 
allele combinations of MolHap2-4 (Figure 17B). Transcriptional activity of MolHap4 was 
significantly decreased to 50% of transcriptional activity of MolHap1 (p<0.001). By 
contrast, transcriptional activity of MolHap1-4 did not differ in THP1 monocytes (Figure 
17C), indicating a cell type-specific effect of the identified MolHaps on HIVEP1 promoter 
activity.  
A  
 
B                                                                  C                                                                 
Figure 17: Transient transfection of MolHaps1-4 in EA.hy926 and THP1 cells A) We identified 
four MolHaps, generated by three SNPs located between positions -1060 to -953, which we 
introduced into a HIVEP1 promoter construct comprising positions -1650 to +79. B) Introduction of 
alleles representing MolHap2 and 3 led to a stepwise decrease of transcriptional activity, 
transcriptional activity of MolHap4 revealed ~50% of the transcriptional activity of MolHap1 in 
EA.hy926 cells. C) We observed no difference in transcriptional activity between MolHap1-4 in 
THP1 cells. White bars indicate transcriptional activity of the pGL3-Control, black bars of the 
pGL3-Basic vector. Transcriptional activity was assessed as relative light units (RLU). WT: wild 
type. ***p<0.001, *p<0.05, ns = not significant.   
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4.3 Identification of cis-active elements affecting HIVEP1 mRNA 
expression  
Since we aimed at investigating how inflammatory factors affect the HIVEP1 expression 
regulation, we functionally characterized the 5'-flanking region of HIVEP1 and determined 
the location of cis-active elements. Therefore, serial promoter deletion constructs 
comprising up to 4.8 kb of the 5'-flanking region of HIVEP1 were designed (Figure 18A). 
Promoter fragments were cloned into the pGL3-Basic vector. Transcriptional activity of 
transiently transfected deletion constructs thereby depended on the ability of inserted 
promoter portions to drive the expression of the firefly luciferase (LUC) gene. The 
pGL3-Control vector, which harbours a SV40 promoter and enhancer leading to a strong 
LUC gene expression, served as positive control for transfection efficiency. 
 
4.3.1 Characterization of the 5'-flanking HIVEP1 structure  
Transient transfection of promoter deletion constructs in EA.hy926 cells revealed basal 
transcriptional activity residing between proximal positions -1097 and -469, since deletion 
constructs -469/+79, -740/+79 and -1097/+79 exhibited moderate transcriptional activity 
(Figure 18B). A significant increase in transcriptional activity was observed for the distal 
deletion construct -1241/+79 compared to construct -1097/+79 (p<0.001), while deletion 
construct -1650/+79 contained the highest transcriptional activity (p<0.01 compared to 
-1241/+79). Transfection of deletion constructs -2288/+79 and -4790/+79, harbouring 
further upstream portions of the 5'-flanking region, resulted in a significant decrease of 
transcriptional activity compared to deletion construct -1650/+79 (both p<0.001). In 
conclusion, the strongest transcriptional activity resided between positions -1650 and 
-1241. Transient transfection of HIVEP1 promoter constructs in THP1 cells demonstrated 
a similar activity pattern as observed in EA.hy926 cells (Figure 18C). 
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Figure 18: Characterization of the HIVEP1 promoter A) Serial HIVEP1 promoter deletion 
constructs were cloned into the pGL3-vector system and transiently transfected into EA.hy926 and 
THP1 cells. B) Moderate transcriptional activity was observed for proximal HIVEP1 promoter 
deletion constructs -469/+79, -740/+79 and -1097/+79 in EA.hy926 cells, suggesting basal 
promoter activity between positions -1097 and -469. Transcriptional activity significantly increased 
for deletion construct -1241/+79 (p<0.001), peaked in construct -1650/+79 (p<0.01), and 
significantly decreased for deletion constructs -2288/+79 and -4790/+79 (both p<0.001) compared 
to deletion construct -1650/+79, indicating strongest promoter activity between distal positions 
-1650 and -1241. C) In THP1 cells, strongest transcriptional activity was identified for deletion 
construct -1650/+79, resulting in a similar promoter architecture as observed in EA.hy926 cells. 
White bars indicate transcriptional activity of pGL3-Control vector driven by a powerful SV40 
promoter and enhancer (EN) (white box), serving as control for transfection efficiency. Black bars 
indicate transcriptional activity of promoter-less pGL3-Basic vector, serving as vector shuttle 
control. Transcriptional activity was assessed as relative light units (RLU). ***p<0.001, **p<0.01, 
*p<0.05, ns = not significant. LUC indicates luciferase gene; black boxes exon 1 5'-UTR; arrow 
indicates TSS.  
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4.3.2 Influence of TNFα and PMA on HIVEP1 promoter constructs’ 
transcriptional activities 
Since HIVEP1 expression was affected by TNFα and PMA treatment (cf. chapter 4.1.1.2), 
we analyzed the effect of these stimuli on HIVEP1 promoter constructs. The impact of 
each stimulus on the transcriptional activity of the deletion constructs is calculated in fold 
induction (FI) values, i.e. promoter constructs’ relative transcriptional activitiy over the 
pGL3-Basic shuttle vector.  
In EA.hy926 cells, stimulation with TNFα did not alter transcriptional activity of deletion 
constructs, since the mean FI was 0.84 (Figure 19).  
 
 
 
 
Figure 19: TNFα had no effect on transcriptional activity of HIVEP1 promoter deletion 
constructs Stimulation of EA.hy926 cells with TNFα (10 ng/mL, 24h) did not influence 
transcriptional activity of HIVEP1 promoter deletion constructs (mean fold induction [FI]=0.84). We 
obtained similar results in THP1 cells. FI was calculated as promoter constructs’ relative 
transcriptional activity over the promoter-less pGL3-Basic vector. Transcriptional activity was 
assessed as relative light units (RLU). 
 
4 Results 
64 
 
pGL3_Basic
pGL3_Control
-469/+79
-740/+79
-1097/+79
-1241/+79
-1650/+79
-2288/+79
-4790/+79
THP1
RLU RLU
FI
7.0
6.5
17.7
8.9
2.3
2.5
2.4
1.0
3.1
basic conditions PMA
FI
1.0
0.5
0.6
0.4
0.5
0.4
0.4
1.0
1.9
RLU
pGL3_Basic
pGL3_Control
-469/+79
-740/+79
-1097/+79
-1241/+79
-1650/+79
-2288/+79
-4790/+79
EA.hy926
RLU
basic conditions PMA
Treatment of EA.hy926 cells with PMA resulted in a decrease in transcriptional activity of 
HIVEP1 promoter deletion constructs (mean FI=0.54) (Figure 20A), while constructs’ 
transcriptional activity was stimulated by PMA leading to a mean FI of 6.75 in THP1 cells 
(Figure 20B). Of note, the strongest effect of PMA was observed for transcriptional activity 
of distal deletion constructs starting with construct -1241/+79. 
 
A  
 
 
 
 
 
 
 
B  
 
 
Figure 20: Cell type-specific effect of PMA on transcriptional activity of HIVEP1 promoter 
deletion constructs A) In PMA-stimulated EA.hy926 cells transcriptional activity of HIVEP1 
promoter deletion constructs was decreased compared to basic conditions (mean fold induction 
[FI]=0.54). B) In THP1 cells, stimulation with PMA led to an increase of transcriptional activity of 
deletion constructs (mean FI=6.75). Cells were incubated with PMA (10-8 M) for 24h. FI was 
calculated as promoter constructs’ relative transcriptional activity over the promoter-less 
pGL3-Basic vector. Transcriptional activity was assessed as relative light units (RLU). 
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 4.3.3 Regulatory effect of an intronic modulator on HIVEP1 expression 
Apart from the localization of cis-regulatory elements within the 5'-flanking regions, 
modulators of gene expression can be found within intronic regions in vicinity of TSS 
(Seshasayee et al., 2000; Kim et al., 2005). Therefore, we analyzed the impact of a 
defined region in intron 1 on the transcriptional HIVEP1 promoter activity. To determine 
the part of intron 1, which may possess a regulatory property on HIVEP1 expression, we 
performed in silico analysis using AliBaba2.1 based on the database of eukaryotic TFs 
(TRANSFAC 7.0). Clustered binding of specificity protein 1 (SP1) and conserved binding 
sites for Wilms’ tumor protein 1 (WT1) were indicated within the first ~350 bp of intron 1 
(Figure 21). Predictions of TF binding were validated using another web-based tool 
PROMO 3.0.2 accessing TRANSFAC 8.3. Subsequently, we added this intronic region to 
HIVEP1 deletion constructs and used it as biotinylated probe in EMSA analysis (cf. 
chapter 4.4.2.2). 
 
 
 
Figure 21: Schematic representation of predicted TFs SP1 and WT1 binding in intron 1 of 
the HIVEP1 gene In silico analysis using AliBaba2.1 (TRANSFAC 7.0) indicated binding sites for 
TFs specificity protein 1 (SP1, green circles) and Wilms’ tumor protein 1 (WT1, red circles) in the 
first about 350 bp of intron 1 in the HIVEP1 gene. Binding of a proposed TF module comprising 
SP1 (triangle) and WT1 (diamond) to intron 1 of the HIVEP1 gene is schematically shown. 
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In EA.hy926 cells, addition of the intronic region, i.e. the first 345 bp of intron 1, to HIVEP1 
deletion constructs, resulted in a significant decrease of transcriptional activity of all 
analyzed deletion constructs (all p-values <0.001, Figure 22A). The constructs 
(-469/+421, -740/+421, -1097/+421, -1650/+421) displayed 50% of the activity (FI values 
≤0.5) of deletion constructs lacking intron 1 (-469/+79, -740/+79, 1097/+79, -1650/+79) 
(Figure 22B). These results demonstrate a strong influence of the intronic modulator on 
HIVEP1 promoter activity in endothelial cells. 
In THP1 cells, addition of the intronic modulator to deletion construct -1650/+79 led to a 
significant ~3-fold increase in transcriptional activity (p<0.01) (Figure 22C/D). Activities of 
deletion constructs -740/+421 and -1097/+421 were instead not affected by the intronic 
region in monocytes, while addition of intron 1 to deletion construct -469/+79, comprising 
the proximal promoter, led to abrogation of transcriptional activity (p<0.01, FI=0.05, Figure 
22C/D). In both cell lines, deletion construct +10/+421, harbouring the isolated intronic 
modulator and exon 1 alone, did not exhibit individual transcriptional activity. This 
indicates that an intronic modulator interacts with distinct 5'-flanking promoter regions in 
both cell lines, altering transcriptional activity in a cell type-specific manner.         
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Figure 22: An intronic modulator regulates cell type-specific HIVEP1 promoter activity A) In 
EA.hy926 cells, addition of a 345 bp portion of intron 1 resulted in significantly decreased 
transcriptional activities of HIVEP1 promoter constructs (all p-values <0.001). B) Effect of the 
intronic modulator displayed as fold induction (FI) demonstrates a ≥0.5-fold reduction of activity of 
constructs harbouring the defined part of intron 1. C/D) Transcriptional activity of deletion construct 
-1650/+79 was significantly increased by addition of intron 1 (p<0.01; FI=3) in THP1 cells, while 
constructs -1097/+79 and -740/+79 remained unaffected. A significant decrease of transcriptional 
activity (p<0.01; FI=0.05) was observed for deletion construct -469/+79 by adding the intronic 
region. FI was calculated as relative transcriptional activity of each construct harbouring the intronic 
region compared to the deletion construct lacking intron 1 (FI=1). Transcriptional activity was 
assessed as relative light units (RLU). ***p<0.001, **p<0.01, ns = not significant. 
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4.4 Analysis of candidate trans-acting factors modulating HIVEP1 
expression regulation 
Since our investigation of the HIVEP1 promoter structure (cf. chapter 4.3.1) indicated that 
the 5 kb of the 5'-flanking region harbour activating regulatory cis-elements, we analyzed 
the interaction of trans-acting factors with the identified promoter region of HIVEP1. 
Therefore, we performed in silico analyses for the prediction of TFBS in the promoter 
region of HIVEP1 using net-based programs AliBaba 2.1 and PROMO 3.0.2. 
Subsequently, we analyzed the impact of predicted TFs on the HIVEP1 promoter in vitro 
using overexpression and EMSA experiments, while in vivo confirmation of TF binding to 
the promoter region was conducted by ChIP analysis. 
 
4.4.1 In silico analyses of putative TFBS in the HIVEP1 promoter 
The first 1500 bp of the 5'-flanking region display a high GC content (74%) and 
computational analysis based on the TRANSFAC 7.0 database suggested binding of Zn 
finger proteins SP1, early growth response factor 1 (EGR1) and WT1, which recognize 
GC-rich sequences (Figure 23). Clusters of SP1 were proposed between positions -1000 
and -1 (relative to the TSS) of the HIVEP1 5'-flanking region. Four conserved EGR1 and 
three WT1 binding sites were predicted between positions -700 to -500. In addition, two 
NF-κB binding sites were indicated in the distal HIVEP1 promoter structure flanking 
position -1200. 
 
 
 
 
Figure 23: Schematic representation of predicted TFBS for SP1, EGR1, WT1 and NF-κB in 
the 5'-flanking region of HIVEP1 Clusters of SP1 binding sites were predicted in the first 1000 bp 
of the 5'-flanking region and two κB-sites, surrounding position -1200 relative to the TSS (arrow). 
Three WT1 and four EGR1 binding sites were predicted at positions -700 to -500.  
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4.4.2 Zn finger proteins SP1, EGR1 and WT1 affect HIVEP1 expression 
To determine the influence of proposed Zn finger containing TFs on HIVEP1 expression 
regulation in vitro, we performed overexpression experiments with SP1, EGR1 or WT1 in 
EA.hy926 cells (cf. chapter 4.4.2.1). EMSA experiments with subsequent antibody 
treatment were conducted to analyze the DNA/protein interactions, i.e. the interaction of 
predicted Zn finger proteins with certain HIVEP1 promoter fragments, in EA.hy926 and 
THP1 cells in vitro (cf. chapter 4.4.2.2). We analyzed in vivo binding of predicted TFs with 
specific antibodies against the Zn finger proteins by ChIP assays (cf. chapter 4.4.2.3) in 
EA.hy926 cells.  
 
4.4.2.1 Cotransfection assays 
We analyzed the impact of TF overexpression on transcriptional activity in all HIVEP1 
deletion constructs, here exemplary shown for deletion constructs -740/+79, -740/+421, 
-1097/+79 and -1097/+421 in EA.hy926 cells. The effect of TF overexpression on 
transcriptional activity was expressed as relative activity of the deletion construct 
compared to the pGL3-Basic shuttle vector (FI=1). Overexpression of SP1 resulted in a 
significant 2.9 to 4.9-fold increase of transcriptional activity of HIVEP1 deletion constructs 
(Figure 24A). The effect was independent of the intronic modulator (all p-values <0.001). 
Similar results were obtained, when EGR1 was overexpressed in EA.hy926 cells. EGR1 
cotransfection led to a significant increase of the transcriptional activity of all HIVEP1 
constructs (all p-values <0.001; 3.8 to 4.8-fold, Figure 24B). By contrast, overexpression 
of WT1 led to a 2.85-fold increase of transcriptional activity of constructs, comprising the 
intronic modulator (both p<0.001; -1097/+421, -740/+421), while a decrease in deletion 
constructs’ activities was observed for constructs lacking intron 1 (both FI=0.5, Figure 
24C). In these cotransfection experiments, we overexpressed the WT1(-KTS) isoform, 
lacking the KTS-motif, i.e. the insertion of the three amino acids lysine-threonine-serine, 
since WT1(-KTS) is described to act as a TF, while WT1(+KTS) rather interacts with 
splicing factors (Roberts, 2005).  
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Figure 24: Cotransfection of SP1, EGR1 and WT1 in EA.hy926 cells SP1 (A) and EGR1 (B) 
overexpression led to a mean ~3.9 (SP1) and ~4.4 (EGR1)-fold increase of transcriptional activity 
of all deletion constructs compared to deletion constructs cotransfected with pCMV shuttle vector. 
C) WT1 overexpression resulted in a mean ~2.85-fold increased transcriptional activity of 
constructs harbouring intron 1 compared to shuttle vector activity, whereas a decrease in activity 
was shown for constructs lacking intron 1. FI was calculated as relative transcriptional activity of 
each construct compared to promoter-less pGL3-Basic (+pCMV) (FI=1). Transcriptional activity 
was assessed as relative light units (RLU). ***p<0.001, *p<0.05.  
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4.4.2.2 EMSAs 
To analyze binding of the predicted TFs to the identified HIVEP1 regulatory elements, we 
performed EMSAs using EA.hy926 and THP1 nuclear extracts. Nuclear extracts were 
isolated from unstimulated or TNFα-stimulated cells to compare interactions of TFs with 
the HIVEP1 promoter regions under basic and inflammatory conditions. THP1 monocytes 
were treated with PMA to analyze differential binding patterns in monocytes compared to 
macrophages. Biotinylated PCR products, harbouring part of intron 1 or the proximal 
HIVEP1 promoter, served as EMSA probes. Sequence-specific binding was visualized 
using the unlabeled PCR fragment (competitor) in a 200-fold molar excess for signal 
competition.  
To analyze the interaction of SP1 and WT1 with the intronic modulator region, we 
designed an EMSA probe (138 bp) according to predicted SP1 and WT1 binding sites in 
intron 1 at position -14 to +124 (Figure 25A). Detection with an anti-biotin antibody 
revealed two specific band shifts (arrows), indicating interaction of EA.hy926 nuclear 
proteins with SP1 and WT1 binding sites, whereas THP1 nuclear proteins showed no 
sequence-specific interaction with the EMSA probe (Figure 25B). To identify the proteins, 
which mediated the specific band shifts by binding to the applied EMSA probe, EMSA 
blots were incubated with a SP1- or WT1-specific antibody to detect binding of the two 
predicted TFs at intron 1. Interaction of SP1 but not WT1 with intron 1 (black arrow) was 
observed for EMSAs performed with EA.hy926 nuclear extracts, while no binding of WT1 
or SP1 was detected in THP1 cells.  
Besides the investigation of TF binding to the intronic modulator, we analyzed the 
interaction of the predicted TF modul comprising SP1, EGR1 and WT1 with the 5'-flanking 
promoter region of HIVEP1. A fragment spanning positions -728 to -462 was used as 
biotinylated probe in EMSA (Figure 26A). Under basic conditions, no specific band shift 
was observed using THP1 or EA.hy926 nuclear extracts (Figure 26B). Differentiation of 
THP1 monocytes into macrophages led to sequence-specific interaction of nuclear 
proteins with the probe (black arrow), while we observed no band shift in PMA-stimulated 
EA.hy926 cells. Another specific band shift was observed when THP1 cells were 
stimulated with TNFα (open arrow). These band shift assays indicated that the region 
between -728 and -462 harbours cis-regulatory elements, differentially recognized by 
nuclear proteins under distinct inflammatory conditions. 
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Figure 25: Interaction of SP1 with the intronic modulator in EA.hy926 cells A) Schematic 
representation of the EMSA probe harbouring SP1 and WT1 binding sites in intron 1. B) EMSA 
analysis, using an anti-biotin antibody, revealed two band shifts (arrows), demonstrating 
sequence-specific interaction of nuclear EA.hy926 proteins with the intron 1 probe (138 bp), 
comprising SP1 and WT1 binding sites. Detection of EMSA blots with a specific SP1 or WT1 
antibody resulted in a defined signal for SP1 but not for WT1, in case of the competed upper band 
(black arrow). No specific band shift was observed for this position using THP1 nuclear extracts 
and no signal was observed by detection with a specific SP1 or WT1 antibody. Sequence-specific 
competitor was applied in a 200-fold excess (8 pmol). Free probe: Unbound oligonucleotides. 
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Figure 26: Stimuli-specific interaction of nuclear proteins with the proximal promoter of 
HIVEP1 A) Schematic representation of the EMSA probe harbouring promoter portion -728 to -462. 
B) Stimulation of THP1 cells with PMA (10-8 M, 72h) or TNFα (10 ng/mL, 24h) resulted in two 
specific band shifts (black and open arrow). No specific band shift was observed in THP1 cells 
under basic conditions. When untreated or with PMA stimulated EA.hy926 nuclear extracts were 
employed, no competable band shift was observed. Sequence-specific competitor was applied in a 
200-fold excess (8 pmol). Free probe: Unbound oligonucleotides. Ø: basic conditions. 
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4.4.2.3 ChIP analysis  
To confirm the binding of potential trans-acting factors in the 5'-flanking region of HIVEP1 
in vivo, we performed ChIP assays using EA.hy926 cells. Interactions of proteins with the 
chromatin were fixed and DNA was sonificated. Subsequently, specific antibodies against 
SP1, EGR1 and WT1 were applied for precipitation of bound cis-regulatory elements. 
Chromatin incubated with magnetic beads alone or with serum, but without antibodies, 
served as negative controls 1 and 2, respectively (Figure 27). PCR was performed to 
amplify specific HIVEP1 promoter elements, for which binding of TFs SP1, EGR1 or WT1 
was suggested (cf. chapter 4.4.1). Positive PCR control was conducted using 10% of 
extracted chromatin (Input) as template.  
The ChIP analysis revealed a specific interaction of SP1 with HIVEP1 promoter portions 
flanking positions -1000 and -400 under basic conditions, while no interaction of EGR1 
and WT1 with the HIVEP1 promoter was detectable in vivo.  
 
 
 
 
 
 
 
Figure 27: The HIVEP1 promoter is bound by SP1 in vivo ChIP analysis in EA.hy926 cells 
demonstrated in vivo binding of SP1 to HIVEP1 promoter portions -469 to -307 and -1097 to -916. 
Chromatin treated with magnetic beads or with beads and serum served as negative control 
(control 1 and 2, respectively). Input: Extracted chromatin served as positive control for PCR. 
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4.4.3 Interaction of nuclear proteins with NF-κB binding sites in the HIVEP1 
promoter 
Since HIVEP1 has been proposed to be involved in NF-κB signaling and HIVEP1 
expression was altered during inflammatory conditions (cf. chapter 4.1.1), we analyzed 
the HIVEP1 promoter region with respect to NF-κB binding motifs. Two conserved NF-κB 
binding sites were predicted (TRANSFAC 7.0) at positions -1236 to -1227 and -1268 to 
-1259, both located in deletion construct -1650/+79, harbouring the major HIVEP1 
promoter activity. To determine if nuclear proteins of EA.hy926 cells interact with these 
predicted NF-κB binding sites in the HIVEP1 promoter region, we designed different 
EMSA probes (Figure 28A), comprising one of the two (probe A or B) or both (probe AB) 
NF-κB binding motifs.  
Application of EMSA probe AB revealed three band shifts (arrows) that were competed 
with the unlabeled probe AB in EA.hy926 cells under basic conditions (Figure 28B). The 
unlabeled EMSA probe A competed each of the three specific band shifts and the 
unlabeled EMSA probe B was able to compete the two lower band shifts (black arrows), 
leaving the residual band shift unaffected (open arrow, Figure 28B). Two different specific 
band shifts (black arrows) were observed when probe A was employed, harbouring the 
predicted NF-κB recognition site at positions -1268 to -1259 (Figure 28B). EMSA probe B 
revealed a specific band shift, comprising the isolated NF-κB binding site at positions 
-1236 to -1227 (Figure 28B). These results indicate specific interactions of nuclear 
proteins in EA.hy926 cells with both predicted NF-κB binding sites in the HIVEP1 
promoter.  
In addition, two of the three specific band shifts (black arrows) observed for EMSA probe 
AB were also competed using a commercial NF-κB consensus site (c) as competitor 
(Lenardo and Baltimore, 1989), substantiating the interaction of NF-κB family members 
with the HIVEP1 promoter portion (Figure 28C). These interactions were not altered when 
EA.hy926 cells were incubated with TNFα (10 ng/mL, 24h), since the three specific band 
shifts were still detectable with identical intensity compared to basic conditions (Figure 
28C/D). Interestingly, the intensity of the three band shifts were reduced to ~50% upon 
incubation of EA.hy926 cells with simvastatin (2.4 µM, 24h), applied alone or in 
combination with TNFα (10 ng/mL, 6h) compared to basic conditions (Figure 28C/D), 
indicating that simvastatin reduces the affinity of nuclear proteins to NF-κB binding sites in 
the HIVEP1 promoter.  
Subsequent detection of EMSA blots with specific antibodies against NF-κB family 
members (RelA, RelB, c-Rel, p105/50, p100/p52) could not demonstrate binding of any of 
the NF-κB factors to predicted NF-κB sites in these EMSA experiments (data not shown). 
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Figure 28: Interaction of nuclear proteins with NF-κB binding sites in the HIVEP1 promoter 
is altered by simvastatin A) EMSA probes were designed harbouring one of the two (probe A or 
B) or both (probe AB) predicted NF-κB binding sites at positions -1236 to -1227 and -1268 to -1259 
in the HIVEP1 5'-flanking region. B) We detected three specific band shifts under basic conditions 
using EMSA probe AB (black and open arrows). The unlabeled EMSA probe A competed all three 
band shifts, while EMSA probe B competed the two lower band shifts (black arrows). Using EMSA 
probe A revealed two and application of EMSA probe B one specific band shift (black arrows) 
under basic conditions in EA.hy926 cells. C) Two of the three band shifts detected (black arrows), 
using EMSA probe AB were also competed using the NF-κB consensus site (c) as competitor 
(Lenardo and Baltimore, 1989). After treatment of EA.hy926 cells with simvastatin (2.4 µM, 24h) 
with or without inflammatory TNFα (10 ng/mL, 6h) background, the intensity of the three band shifts 
was reduced, while TNFα alone (10 ng/mL, 24h) had no influence on the interaction of nuclear 
proteins with EMSA probe AB. D) Densitometric analysis revealed a significant reduction of the 
three band shifts to ~50% upon simvastatin treatment compared to basic conditions or treatment of 
cells with TNFα alone. Densitometric analysis involved three EMSA blots. Basic conditions were 
used as reference and set 1. **p<0.01, ns = not significant. Ø: basic conditions.  
 
4.5 Knockdown of HIVEP1 by siRNA 
Since there is scare information and data on HIVEP1 signaling, we planned a siRNA 
approach to identify HIVEP1 target genes. Knockdown efficiency was monitored at the 
HIVEP1 mRNA level by semiquantitative PCR. The first step was to analyze the existence 
of HIVEP1 transcripts predicted by ENSEMBLE database in EA.hy926 and THP1 cells. 
For this purpose, we conducted PCRs using cDNA as template and different primer pairs 
(appendix, Figure A2, Table A1). The results of the sequential analysis of HIVEP1 
transcripts supposed existence of the full length HIVEP1 transcript, comprising exon 1c to 
9, coding for full length HIVEP1 in EA.hy926 and THP1 cells (appendix, Figure A2). In 
addition, a transcript harbouring the alternative exon 5 and exons 6 to 9, and another 
transcript containing two alternative exons, termed 1a and 1b, were detected. We choose 
exon 8 as target for the siRNA to knockdown the detected HIVEP1 transcripts, which code 
for full length HIVEP1 and a putative isoform, harbouring the C-terminal HIVEP1 residue 
(exon 5 to 9). The sequence of the siRNA duplex was designed using the siRNA selection 
program “siRNA at WHITEHEAD” (format: AA(N19)TT) as described by Pei and Tuschl 
(Pei and Tuschl, 2006). Since many off-target effects (i.e. down-regulation of unintended 
targets) of siRNAs exist (Jackson and Linsley, 2010), off-target effects were additionally 
checked using the net-based program “ParAlign”. The siRNA duplex was elected, for 
whom only two putative off-targets were predicted: the pseudogene 
teratocarcinoma-derived growth factor 6 (TDGF6) and the Ras protein-specific guanine 
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nucleotide-releasing factor 2 (RASGRF2). A commercial control siRNA duplex (low GC, 
Invitrogen), which displays a minimized sequence homology to any known vertebrate 
transcript, served as control for sequence-independent effects of siRNA transfection. 
When PCR was conducted using primers located in exon 1(c) and at the start of exon 4, 
transient transfection of EA.hy926 cells with the HIVEP1 siRNA duplex targeting exon 8 
for 48h resulted in a ~50% knockdown of HIVEP1 mRNA expression compared to the 
transfected siRNA control duplex (Ctrl) (Figure 29A). For the PCR product comprising 
exon 8, a ~75% knockdown of HIVEP1 was achieved compared to control, independent of 
siRNA concentrations applied (200 and 300 nM; Figure 29B). Thus, the designed siRNA 
duplex targeting exon 8 is able to knockdown HIVEP1 transcripts by transient transfection 
of 200 -300 nM siRNA using oligofectamine for 48h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Knockdown of HIVEP1 by siRNA in EA.hy926 cells A siRNA duplex (200 or 300 nM) 
targeting HIVEP1 exon 8 was transiently transfected into EA.hy926 cells. We observed a ~50% (A) 
and a ~75% (B) knockdown of HIVEP1 compared to the control siRNA (Ctrl) after 48h, for the PCR 
product comprising exon 1(c) to 4 and exon 8, respectively. RNA was isolated and used for cDNA 
synthesis. RP27-PCR served as loading control. Ctrl, siRNA control duplex.  
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5 DISCUSSION 
5.1 Proximal and distal regulatory elements for HIVEP1 
expression 
The transcriptional control of active genes is mediated by interaction of trans-acting 
factors at specific cis-active elements in the promoter region to mediate precise spatial 
and temporal gene expression (Maston et al., 2006). As described in chapter 1.3, the 
promoter region can be subdivided into a core promoter region, harbouring recognition 
sequences necessary for PIC assembly, and proximal promoter regions, possessing 
binding sites for cofactors. In addition, further distant regulatory elements may take part in 
gene expression regulation by silencing or enhancing specific gene expression (Maston et 
al., 2006).   
By a multistage approach following GWA, including individuals from the MARTHA, 
FARIVE and MEGA study, a SNP (rs169713) located 90 kb upstream of the HIVEP1 gene 
has been associated with VT (Morange et al., 2010). It has been suggested, that this SNP 
is a marker of a chromosomal region susceptible for VT, thereby indicating that functional, 
yet identified, SNPs may be located within the HIVEP1 gene. In a further GWA, using 
more genetic markers (dense fine map) in formerly proposed phenotype-associated loci, 
the HIVEP1 gene was confirmed to be highly associated (HIVEP1 exon 4) with VT 
(Germain et al., 2011). The region encompassing the tagging SNP rs169713 was 
analyzed in this study with regard to its potential enhancer or silencer capacity for the 
HIVEP1 gene, since enhancers may be located even hundreds of kbp away from their 
target gene (Maston et al., 2006). One regulatory element, for example, controls the 
expression of three different genes, IL-4, IL-13 and IL-5, spread over 120 kb at human 
5q31 (Loots et al., 2000) and the α-globulin gene expression is under the control of 
elements positioned 60 kb upstream (Higgs et al., 1990; Higgs et al., 2008). In our 
analysis, a 319 bp region harbouring the rs169713 T allele was found to enhance the 
pGL3-Promoter activity using reporter gene assays in EA.hy926 and THP1 cells. Thus, 
the region 90 kb upstream of HIVEP1 may harbour allele-dependent enhancer capacity 
for HIVEP1. Cloning of the potential enhancer element in a vector, comprising the 
identified HIVEP1 proximal promoter region in front of the luciferase gene instead of the 
minimal SV40 promoter, would demonstrate the interplay of the enhancer with the 
HIVEP1 promoter and support this hypothesis.   
Besides the analysis of the potential enhancer, reporter gene asssays revealed a core 
promoter region sufficient to guide basal HIVEP1 expression between positions -1099 and 
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-469, whereas the strongest transcriptional activity was observed between positions -1650 
and -1241 in both, endothelial and monocytic cells. An intronic modulator affected HIVEP1 
expression in a cell type-specific manner. In THP1 cells, the intronic modulator exclusively 
increased transcriptional activity of deletion construct -1650/+79, harbouring the most 
considerable promoter activity, and decreased transcriptional activity of the very proximal 
construct -469/+79. This result indicates that the intronic modulator differentially interacts 
with the core and proximal promoter region of HIVEP1 in monocytic cells. In endothelial 
cells, the intronic modulator strongly influenced the core and proximal promoter activity by 
decreasing HIVEP1 5'-flanking deletion constructs’ transcriptional activities, indicating that 
crucial cis-active regulatory elements for endothelial HIVEP1 expression are positioned in 
intron 1. That intronic regions may possess cell type-specifc promoter activity has also 
been demonstrated for the kidney brain (KIBRA) gene promoter (K. Guske, PhD thesis), 
the SM α-actin (SMαA) promoter (Kawada et al., 1999) or the erythroid-specific GATA-1 
gene expression regulation (Seshasayee et al., 2000).  
 
5.2 Involvement of Zn finger proteins and NF-κB in HIVEP1 
expression regulation 
In silico analyses in general predict the binding of distinct TFs to the analyzed DNA 
sequence, e.g. the promoter sequence of the gene of interest. These predictions of TFs 
and TF families, which might be involved in the expression regulation of the analyzed 
gene, e.g. HIVEP1, are limited, since they are exclusively based on DNA sequence. 
However, different physiological conditions may alter the affinity of TFs to their consensus 
sequences, which are not considered in computational analyses. On the one hand, the 
relative respective abundance of distinct TFs is altered upon different stimulations, as 
shown for EGR1, which expression is increased upon PMA stimulation (Silverman and 
Collins, 1999), leading to synergistic interactions or to competition at consensus sites, as 
described for Zn finger proteins SP1, EGR1 and WT1 at their overlapping binding sites in 
the TXA2 promoter (Gannon et al., 2009). On the other hand, distinct physiological states 
of cells may mediate posttranslational modifications that could be necessary for TF 
activation or TF translocation into the nucleus, as shown for NF-kB family members 
(Zhong et al., 2002). Since in silico analyses predicted binding sites for Zn finger proteins 
SP1, WT1 and EGR1 in the HIVEP1 promoter region, the impact of these factors on 
HIVEP1 expression regulation was analyzed under basic and stimulatory conditions.  
Overexpression, EMSA and ChIP experiments revealed that SP1 is involved in basal 
HIVEP1 expression regulation in endothelial cells by binding to the repressive intronic 
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modulator region as well as to positions -1000 and -400 in the 5'-flanking region of 
HIVEP1 in EA.hy926 cells. The ubiquitously expressed SP1 binds with high affinity to 
GC-boxes and its activity is altered by posttranslational modifications, such as 
phosphorylation (Chu and Ferro, 2005), or by interaction with other proteins, such as 
tumor suppressors and oncogenes (Black et al., 2001). Binding of SP1 molecules to two 
or more consensus sites has a synergistically activating effect and SP1 binding to another 
SP1 molecule leads to the so-called superactivator capacity of SP1 (Pascal and Tjian, 
1991). As SP1 recruits TBP/TFIID and the chromatin remodeling complex SWI/SNF, it is 
known to initiate the gene transcription of TATA-less genes (Wierstra, 2008). No TATA 
motif (TATA-A/T-AA-A/G) was found in the first 50 bp of the HIVEP1 5'-flanking region, 
indicating that the HIVEP1 promoter lacks a TATA box. Instead, the first 1500 bp of the 
HIVEP1 5'-flanking region harbour a GC content of 74% and a CpG island is predicted 
between positions -180 to +570 (UCSC Genome Browser, http://genome.ucsc.edu/), 
including the intronic modulator. GC-rich promoters are typically lacking a TATA-box 
(Carninci et al., 2006), suggesting HIVEP1 to be transcriptionally controlled by a CpG 
island promoter.  
In THP1 cells, the intronic modulator exclusively increased transcriptional activity of 
deletion construct -1650/+79 harbouring the most considerable promoter activity. Our 
EMSAs did not reveal any binding of SP1 to the intronic modulator under basic conditions, 
while SP1 overexpression increased transcriptional activity of HIVEP1 promoter deletion 
constructs in monocytes (data not shown). This suggests an interaction of TFs that bind 
between positions -1650 and -1097 in the HIVEP1 5'-flanking region with the intronic 
modulator in THP1 monocytes.  
Since SP1 increased the promoter activity in cotransfection assays in THP1 cells, SP1 is 
suggested to be involved in basal HIVEP1 expression by binding to the 5'-flanking region 
in THP1 and to both, the 5'-flanking and intronic region as shown in EMSA, ChIP and 
cotransfection assays, in EA.hy926 cells.   
In addition to SP1, EGR1 and WT1 were able to significantly alter HIVEP1 expression. 
While overexpression of EGR1 increased transcriptional activity of all promoter deletion 
constructs, WT1 exclusively increased transcriptional activities of constructs comprising 
the intronic region in EA.hy926 cells, demonstrating the modulating impact of intron 1 on 
HIVEP1 expression. The tumor suppressor WT1 plays a pivotal role during development. 
It is predominantly expressed in the kidney and genital organs (Rauscher, 1993), while we 
observed endogenous expression of WT1 in endothelial EA.hy926 and monocytic THP1 
cells using RT-PCR. WT1 acts both, as a transcriptional repressor and activator, 
depending on the presence of associated proteins, which modulate the regulatory 
potential of WT1 (Rauscher, 1993). Upon association with p53, WT1 has been described 
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as a potent transcriptional activator for the growth arrest and DNA damage-inducible 
protein GADD45 (Zhan et al., 1998). Since the HIVEP1 isoform GAAP1 increases the 
expression of tumor suppressor gene p53 (Lallemand et al., 2002), the observed 
activating effect of WT1 overexpression on HIVEP1 promoter constructs comprising the 
intronic modulator could be a positive feedback mechanism for HIVEP1 expression. 
Thereby, binding of the p53-WT1 complex to the regulatory intronic region of HIVEP1 
leads to upregulation of HIVEP1 expression, in turn increasing p53 expression by GAAP1. 
Since our EMSA experiments revealed binding of SP1, and not WT1 to the intronic 
modulator under basic conditions, certain physiological states could be crucial for the 
interaction of the p53-WT1 complex with the HVEP1 intronic modulator. GAAP1 and not 
full length HIVEP1 is involved in this hypothesized feedback mechanism. Since WT1 has 
been found to colocalize and interact with spliceosomal components (Larsson et al., 1995; 
Davies et al., 1998) and GAAP1 arises from alternative splicing, binding of WT1 to the 
intronic modulator could result in alternative splicing of HIVEP1 pre-mRNA, generating 
GAAP1. Additionally, p53 expression is upregulated by EGR1 (Nair et al., 1997) and was 
shown to form a complex with EGR1 (Liu et al., 2001). Thus, EGR1 may be involved in 
the p53-HIVEP1-feedback mechanism, since EGR1 overexpression significantly 
increased HIVEP1 promoter activity. EGR1 belongs to the group of “immediate-early 
response genes”, indicating that it is rapidly and transiently induced in response to certain 
stimuli. Those stimuli include shear stress, mechanical injury, hypoxia, ROS and the 
plateled-derived growth factor (PDGF), which are implicated in the development of VD 
(Silverman and Collins, 1999). Therefore, EGR1 target genes, such as TNFα, IL-2, 
ICAM-1 and tissue factor (Yao et al., 1997; Skerka et al., 1995; Maltzman et al., 1996; Cui 
et al., 1996), are involved in the pathogenesis of VD. In this respect, the HIVEP1 gene, 
which was shown in this work to be induced by inflammatory stimuli and whose locus is 
associated with VT, could be another EGR1 target gene involved in the development of 
VD.  
EGR1, SP1 and WT1 recognize similar GC-rich consensus sequences and overlapping 
binding sites are often found in promoters (Silverman and Collins, 1999). An identical 
situation for the HIVEP1 promoter is described in this work. The interplay between SP1, 
EGR1 and WT1 in gene expression regulation has already been reported for several 
genes, such as the human copper-zinc superoxide dismutase gene (Minc et al., 1999) or 
the TXA2 gene (Gannon et al., 2009). SP1 occupies the consensus sites under basic 
conditions, providing basal gene expression, while stimulation, for example with PMA, 
induces EGR1 expression (Silverman and Collins, 1999). Subsequently, EGR1 competes 
with SP1 and is able to displace SP1 at their overlapping consensus sites (Kubosaki et al., 
2009) leading to enhanced gene expression, as shown for TXA2 (Gannon et al., 2009) 
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and PDGF A-chain gene expression (Khachigian et al., 1995). Notably, we only observed 
EGR1 protein expression in EA.hy926 cells and activated monocytes after stimulation with 
PMA (data not shown). Thus, altered HIVEP1 expression, at least during the 
differentiation of monocytes to macrophages may be mediated in part by increased EGR1 
protein expression. WT1 in turn is able to compete with EGR1 at its binding sites 
(Rauscher et al., 1990). Detection of EMSA blots with a SP1- or WT1-specific antibody 
demonstrated binding of SP1 and not WT1 to the intronic modulator under basic 
conditions. In addition, ChIP analyses under basic conditions revealed binding of SP1 and 
not of EGR1 or WT1 to their overlapping consensus sites in the HIVEP1 promoter, 
indicating that SP1 is involved in basal HIVEP1 expression. Stimulation of cells with PMA 
instead could lead to binding of EGR1 to the GC-rich elements displacing SP1 and 
increasing HIVEP1 expression. However, the distinct physiological conditions, in which 
EGR1 and WT1 act on HIVEP1 expression regulation, remain to be investigated in detail.  
Since binding of recombinant HIVEP1 to NF-κB sites in enhancer and promoter regions 
has been shown in several studies (cf. chapter 1.4.2) and two NF-κB binding sites were 
predicted by computational analysis in the 5'-flanking of HIVEP1, we performed EMSAs to 
analyze the interaction of nuclear proteins with HIVEP1 NF-κB consensus sites at 
positions -1268 to -1227. EMSA demonstrated binding of EA.hy926 nuclear proteins to 
NF-κB sites in the HIVEP1 promoter, which confirms that TFs binding to NF-κB consensus 
sites are involved in HIVEP1 expression regulation. Notably, EMSA probes harbouring 
one of the two NF-κB sites were able to compete those band shifts emerged by interaction 
of nuclear proteins with the EMSA probe containing both NF-κB sites, indicating that the 
binding of TFs to one of the two NF-κB consensus sequences influences interaction of 
TFs with the other NF-κB site in the HIVEP1 promoter. However, no signal at competed 
band shifts was observed, when EMSA blots were detected with antibodies against NF-κB 
family members. On the one hand, binding of a protein to a DNA sequence leads to 
changes in protein conformation, which in turn could mask the epitope recognized by the 
used antibody. On the other hand, antibodies that are useful in western blots do not 
necessarily fit in EMSA, since denatured proteins are applied in western blots and native 
proteins in EMSA experiments. Indeed, a commercial NF-κB consensus sequence 
(Lenardo and Baltimore, 1989) was an effective competitor in these EMSA experiments, 
confirming the hypothesis that, besides Zn finger proteins, NF-κB family members are 
involved in HIVEP1 expression regulation by binding to the HIVEP1 promoter.  
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5.3 Impact of genetic variants on HIVEP1 promoter activity 
Genetic variants residing within or in close proximity to TFBS may influence the interaction 
of trans-acting factors with their consensus sequences leading to altered gene expression. 
Each nucleotide change in the consensus sequence may alter the TF binding, i.e. 
weakening TF binding affinity to this consensus site or completely disrupting the 
interaction (Telgmann et al., 2009). Alterations of TF binding patterns due to the existence 
of different alleles at the locus have already been demonstrated for different promoter 
regions (Dördelmann et al., 2008; Hagedorn et al., 2009). In this respect, we analyzed the 
impact of HIVEP1 MolHap1-4, generated by three adjacent SNPs (rs1574343_A>C, 
rs1574166_C>G, rs3902984_A>C) at positions -1060 to -953, on HIVEP1 promoter 
activity in the context of deletion construct -1650/+79, harbouring the major promoter 
activity. Step wise alteration of the wt sequence revealed a step wise decrease of 
transcriptional activity. This observation indicates a change in TF affinities or binding 
patterns at consensus sites, harbouring the analyzed SNPs. In silico analysis predicted a 
change for binding patterns generated by rs1574166_C>G and rs3902984_A>C. A 
substitution of the rs1574166 C allele with the minor G allele predicted to lead to the 
deletion of the consensus site for TF Yin-Yang (YY-1), which binds to the Inr element (Lee 
et al., 1993), and to the addition of two SP1 binding sites. Addition of a binding site for the 
TF family activator protein-2α (AP-2α) was supposed for the site including the rs3902984 
minor C allele. MolHap4 comprises both, the rs1574166 and rs3902984 minor alleles, and 
displayed a transcriptional activity reduced to 50% compared to that of wt (MolHap1). 
Thus, the change of TF binding patterns, especially the gain of an AP-2α consensus site, 
could lead to the decreased HIVEP1 promoter activity observed for MolHap4, since AP-2α 
TFs act also as a repressor and compete with SP1 at its binding sites (Mitchell and 
DiMario, 2010), which has been shown in here to be crucial for basal HIVEP1 expression. 
 
5.4 Pro- and antiinflammatory stimuli regulate HIVEP1 expression 
5.4.1 Modulation of HIVEP1 expression by cytokines  
As HIVEP1 binds to the NF-κB consensus sequence (Muchardt et al., 1992) and has been 
shown to be expressed in human atherosclerotic plaques (Morange et al., 2010), HIVEP1 
has been suggested to be involved in inflammatory signaling cascades. Our analysis from 
available microarray datasets suggested an influence of inflammatory stimuli on HIVEP1 
expression. In this work, incubation of EA.hy926 cells and monocytes with the cytokines 
TNFα and IL-1β increased HIVEP1 mRNA expression, while relatively high HIVEP1 
mRNA expression was detected in macrophages without stimulation in this study. The 
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increase of HIVEP1 expression by PMA and TNFα was also detected at the protein level 
in THP1 cells, suggesting HIVEP1 mRNA level as an indicator for HIVEP1 protein 
amounts in untreated and stimulated monocytes. By contrast, in EA.hy926 cells, lower 
HIVEP1 mRNA expression translated into increased HIVEP1 protein concentrations under 
basic conditions. In EA.hy926 cells, TNFα stimulation did not result in higher HIVEP1 
protein expression. In addition, TNFα had no effect on HIVEP1 promoter activity in neither 
cell line, whereas EMSA analyses revealed differential binding of THP1 nuclear proteins 
after stimulation with TNFα and PMA to the HIVEP1 promoter, indicating that the region 
between -728 and -462 harbours cis-regulatory elements, differentially recognized by 
nuclear proteins under distinct inflammatory conditions. Compared to TNFα, PMA altered 
transcriptional activity of deletion constructs in THP1 and EA.hy926 cells.  
Taken together, these results indicate that changes in TF/promoter interaction do not 
necessarily result in altered HIVEP1 expression but may affect mRNA stability, dependent 
on distinct inflammatory signals and cell types. mRNA stability is estimated to control the 
translation efficiency of ~10% of human genes. While housekeeping-genes provide 
mRNAs with long and invariant half-lives, short mRNA half-lives are characteristic for 
immediate-early response genes, such as oncogenes and cytokines (Bolognani and 
Perrone-Bizzozero, 2008). In that respect, TNFα has been reported to influence mRNA 
stability by affecting the 3'-UTR of a given gene (Matsumiya et al., 2010). Usually, the 
3’-UTR harbours the sequences that affect mRNA in/stability, such as the 
adenylate-uridylate rich element (ARE) AUUUA (Shaw and Kamen, 1986), which can lead 
to mRNA stabilization, e.g. by Hu proteins, or degradation, e.g. by tristetraprolin (TTP), 
depending on the binding protein (Jaksik and Rzeszowska-Wolny, 2012). The 3'-UTR of 
HIVEP1 possesses AU-stretches, of which one is similar to the ARE (Fan and Maniatis, 
1990), indicating that HIVEP1 expression may be influenced by mRNA de/stabilization 
processes. Thus, in TNFα-stimulated EA.hy926 cells, increased HIVEP1 mRNA levels 
may result from increased HIVEP1 mRNA stability by recruitment of TNFα-induced 
RNA-binding proteins, which protect HIVEP1 mRNA from degradation, delivering a stabile 
mRNA depot that can be rapidly used for protein synthesis. Since the detected HIVEP1 
protein expression does not alter upon TNFα stimulation compared to basic conditions, 
the HIVEP1 protein turn over may be increased by TNFα challenge, in contrast to the 
HIVEP1 mRNA expression. Combination of distinct inflammatory cytokines (TNFα, IL1-β, 
IL-4) may result in an increased HIVEP1 protein expression. In THP1 cells, TNFα may 
alter TF binding patterns, which leads to an increased HIVEP1 mRNA stability that is 
translated in increased HIVEP1 protein amount compared to basic HIVEP1 expression 
level in monocytes.  
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5.4.2 Impact of statins on HIVEP1 expression 
Since the antiinflammatory, so-called pleiotropic actions of statins have been suggested to 
also depend on altered protein interaction at NF-κB consensus motifs (Dichtl et al., 2003), 
we analyzed the impact of commonly clinically used statins on HIVEP1 expression in vitro. 
While HMG-CoA reductase inhibitors simvastatin, atorvastatin and rosuvastatin led to a 
significantly decreased HIVEP1 expression, pravastatin and the antiinflammatory COX 
inhibitor aspirin (Yin et al., 1998), as a control, did not affect HIVEP1 expression, 
suggesting a substance-specific effect of statins on HIVEP1 expression. More importantly, 
in TNFα-stimulated endothelial cells, high-dose atorvastatin challenge led to a 
paradoxically increased HIVEP1 expression. Dose-dependent opposed effects of 
atorvastatin on endothelial cell migration and proliferation as well as on angiogenesis 
have been reported. Thereby, low-dose atorvastatin enhanced angiogenesis in mice as 
well as migration and proliferation of endothelial cells, while high-dose atorvastatin 
reversed the effects (Weis et al., 2002). Simvastatin was shown to dose-dependently 
increase the expression of TNFα type I receptor (TNFαRI) (Tang et al., 2006) and 
pravastatin as well as fluvastatin were able to induce TNFα production in monocytes 
under distinct conditions (Takahashi et al., 2005), suggesting that high doses of 
atorvastatin may also be able to potentiate the TNFα-mediated HIVEP1 expression by 
increasing the TNFαRI expression or TNFα production during inflammatory conditions. 
Otherwise, simvastatin and rosuvastatin were able to compensate the TNFα-induced 
HIVEP1 expression below basic HIVEP1 mRNA expression, suggesting that simvastatin 
and rosuvastatin may be more effective as atorvastatin in inflammatory signaling involving 
HIVEP1. In addition, simvastatin was able to reduce the interaction of nuclear proteins 
with NF-κB sites in the HIVEP1 promoter. This observation confirms the by Dichtl et al. 
(Dichtl et al., 2003) previously described effect of simvastatin to alter the NF-κB binding 
affinity to κB consensus sites, here demonstrated at consensus sites in the HIVEP1 
promoter. Statins are able to mediate their antiinflammatory potential by reducing the 
amount of active Rho resulting in a reduction of NF-kB activation (Sposito and Chapman, 
2002). In hypercholesterolemic individuals, simvastatin was shown to decrease TNFα and 
IL-1β levels (Ferro et al., 2000), indicating that simvastatin is able to mediate its effect on 
HIVEP1 expression by decreasing cytokines. Use of rosuvastatin in apparently healthy 
individuals significantly reduced the occurrence of VTE (Glynn et al., 2009), while a 
prospective study of pravastatin did not reveal any effect on VTE (Freeman et al., 2011). 
A recent meta-analysis regarding the effect of statins in the prevention of VTE, revealed a 
protective effect of statin use on VTE and DVT (Pai et al., 2011). In addition, statin 
application in patients with atherosclerosis was demonstrated to be associated with a 
significant reduction in VTE occurrence, thereby a dose-related statin response was 
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observed (Khemasuwan et al., 2011). A recent prospective cohort study regarding 
unintended effects of statin use gave a hint that certain statins may have a protective 
impact on VTE (Hippisley-Cox and Coupland, 2010). In conclusion, the demonstrated 
effect of certain statins, especially simvastatin and rosuvastatin, on HIVEP1 expression 
together with the documented effects of statins on VT in several studies, underline the 
involvement of HIVEP1 in inflammatory processes and the link of HIVEP1 to VT.  
However, it has to be mentioned that our findings have not yet been validated fully at the 
protein level. A HIVEP1 antibody against the C-terminal residue of HIVEP1, located in 
exon 9, was used in this work, while the PCRs for documentation of statin effects on 
HIVEP1 expression were performed with primers, positioned in the N-terminal HIVEP1 
residue, generating a PCR fragment comprising exon 1c, 2, 3 and the start of exon 4. 
There is evidence that, besides full length HIVEP1, the N- and C-terminal part of HIVEP1 
may exist independently and be regulated differently resulting in two separate HIVEP1 
proteins. Firstly, both, recombinant N- and C-terminal HIVEP1, each harbouring one set of 
Zn fingers, had been shown to bind to NF-κB sites independently (Fan and Maniatis, 
1990). Secondly, the results regarding HIVEP1 transcripts, obtained by sequential PCRs 
in combination with the predictions from ENSEMBLE und UCSC database indicated that 
alternative splice events or different TSS in front of HIVEP1 exon 4 or 5 would result in a 
transcript harbouring the C-terminal part, i.e. HIVEP1 exon 5 to 9. The 70 kDa HIVEP1 
isoform GAAP1 lacks exon 4 and recombinant GAAP1 was exclusively found in the 
nucleus, when the PEST-like domain was depleted (Lallemand et al., 2002). Thus, the 55 
kDa isoform detected by western blot analysis in this work might be encoded by exon 5 to 
9 and lack the PEST-like domain, explaining its smaller size and exclusive nuclear 
location. Third, to date there are no studies, which demonstrated the existence of a full 
length HIVEP1 protein in vivo. However, we also observed the decreasing effect of, for 
example, simvastatin on HIVEP1 expression in EA.hy926 cells by PCR amplifying a 
fragment comprising exon 5 to 9, even with smaller effects. This observation suggests that 
a full length HIVEP1 mRNA transcript is regulated by application of statins or that C- and 
N-terminal transcripts are both influenced in a similar manner by statin application. In 
addition, increased HIVEP1 expression upon inflammatory conditions could be detected 
on both, mRNA (N-terminal) and protein level (C-terminal) in THP1 monocytes. In 
conclusion, besides the antibody against the C-terminal residue, another HIVEP1 antibody 
recognizing the N-terminal residue of HIVEP1 could confirm the effect of statins on 
HIVEP1 expression at the protein level.  
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5.5 Nuclear localization of endogenous HIVEP1 in endothelial 
cells 
The cellular localization of endogenous HIVEP1 has not yet been studied using a 
commercial antibody. HIVEP1 was detected within the nuclei of osteosarcoma cells using 
an antibody against the C-terminal part of HIVEP1 (Fan and Maniatis, 1990), while the 
HIVEP1 isoform GAAP1, lacking exon 4, was found in both, the cytoplasm and the 
nucleus of hepatocarcinoma cells (Lallemand et al., 2002). Exclusive nuclear localization 
was reported, when the PEST-like sequence of recombinant eGFP-tagged GAAP1 had 
been deleted (Lallemand et al., 2002).  
In this study, immunofluorescence of endogenous HIVEP1 in endothelial cells revealed 
exclusive nuclear localization of HIVEP1 using an antibody against the C-terminal residue 
of HIVEP1. In accordance to this finding, application of the same HIVEP1 antibody in 
western blot analysis showed exclusive nuclear localization of the detected ~55 kDa 
HIVEP1 isoform in several cell lines (cf. chapter 4.1.3). Thus, endogenous HIVEP1 
isoforms harbouring the C-terminal residue are localized in the nucleus of endothelial cells 
EA.hy926. Subsequent immunofluorescence experiments performed with an antibody 
against the N-terminal part of HIVEP1 would support these findings of exclusive nuclear 
localization of N- and C-terminal HIVEP1. If HIVEP1 is already localized in the nucleus 
under basic conditions to permit target gene expression, this would be in contrast to TFs 
of the NF-κB family, which have to be translocated into the nucleus upon stimulation. 
 
5.6 Conclusion 
VT is the third most common VD after ischemic stroke and mycocardial infarction 
(Reitsma et al., 2012). In addition to mechanical stress due to trauma-derived injury of the 
vein wall or to chemical stress induced by ROS or sepsis, which all result in endothelial 
“dysfunction”, the individual balance of pro- and anticoagulants considerably influences 
the development of thrombus formation at the site of “injury”. The individual level of 
coagulation factors is determined by “classical” genetic risk factors for VT, such as 
deficiency of the anticoagulation factor antithrombin or the increase of the procoagulant 
prothrombin (~50%; Reitsma et al., 2012). Since VT is a complex disease and residual 
idiopathic VT cannot be explained by the above mentioned “classical” genetic risk factors, 
it is conceivable that both, rare genetic variants with a strong effect and multiple common 
SNPs with a more moderate impact, may determine the individual genetic susceptibility for 
the remaining VT (Morange and Trégouët, 2011). In that respect, GWAs were performed 
(Trégouët et al., 2009; Morange et al., 2010) to identify new genetic risk factors for VT as 
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a non-hypothesis driven approach. In addition to the nuclear factor of activated T-cells 
cytoplasmic 3 (NFATC3) and the protein tyrosine phosphatase receptor type F (PTPRF) 
gene, the HIVEP1 locus on chromosome 6 was identified as a susceptible locus for VT. In 
a multistage approach following the first GWA performed for VT, including ~6000 VT 
cases and ~7000 healthy individuals, a tagging SNP located 90 kb upstream of HIVEP1 
(rs169713) was shown to be replicatively associated with VT (Morange et al., 2010). In a 
subsequent GWA, performed with dense fine mapping, a SNP (rs2228220) in HIVEP1 
exon 4 was found to be associated with VT (Germain et al., 2011). HIVEP1 protein 
function and gene regulation are poorly understood to date, except that recombinant  
N- and C-terminal HIVEP1 bind to NF-κB consensus sequences within regulatory 
elements of genes involved in inflammatory processes in vitro (Baldwin et al., 1990; 
Muchardt et al., 1992; Fan and Maniatis, 1990). In the current study, we were able to 
demonstrate that I) HIVEP1 expression is increased under inflammatory conditions in 
endothelial cells and monocytes/macrophages; II. an intronic modulator is implicated in 
cell type-specific HIVEP1 expression regulation; III. NF-κB and Zn finger proteins SP1, 
EGR1 and WT1 are involved in HIVEP1 expression regulation; IV. simvastatin decreases 
the binding affinity of NF-κB to its binding sites in the HIVEP1 promoter region; V. 
simvastatin, rosuvastatin and low-dose atorvastatin decrease the HIVEP1 expression in 
endothelial cells under inflammatory conditions. Interestingly, a protective impact of statins 
on VTE was observed by a recent meta-analysis of statin use in the prevention of VTE 
(Pai et al., 2011) and a recent prospective cohort study regarding unintended effects of 
statin use suggested a protective impact on VTE by certain statins (Hippisley-Cox and 
Coupland, 2010). The identification of additional common VT-associated SNPs will require 
much larger GWAs, including more than 100 000 individuals, as shown for the 
identification of novel SNPs for CAD by studying 140 000 individuals (Schunkert et al., 
2011) or more than 200 000 individuals for blood pressure or hypertension by Ehret et al. 
(Ehret et al., 2011). Whether HIVEP1 is causally involved in VT development may be 
further evaluated in appropriate animal and clinical studies. Our results indicate a 
prominent effect of certain statins (substance-specific) on HIVEP1 expression and may 
serve as a link between statin use and prevention of VT and therefore VTE development.  
6 Outlook 
91 
 
6 OUTLOOK 
Since data on HIVEP1 signaling is rather scarce to date, future HIVEP1 knockdown 
studies using siRNA and subsequent microarray analysis are warranted to identify 
potential HIVEP1 target genes and to substantiate the role of HIVEP1 as an inflammatory 
TF during the development of VT. Overexpression of HIVEP1 may be used to confirm the 
results obtained by knockdown experiments. An up to ~75% HIVEP1 knockdown was 
achieved in the current work documented by RT-PCR, but still has to be confirmed at the 
protein level. To investigate the existence of two separate and independent N- and 
C-terminal HIVEP1 protein isoforms expressed from alternative TSS, the analysis of a 
potential TSS upstream of exon 4 or 5 could be performed by 5'-rapid amplification of 
cDNA ends (5'-RACE). Since CpG island promoters are characterized by broad TSS 
distribution (Carninci et al., 2006), we suggest the HIVEP1 gene to be transcribed from 
different independent TSS, which may be used in a cell type-specific manner.   
To underline the involvement of HIVEP1 during inflammatory conditions in vivo, future 
studies should involve animal models with inflammatory background. TNFα-transgenic 
mice in comparison to wt mice could be used to study the impact of different HIVEP1 
expression levels on vascular phenotypes. The involvement of NF-κB signal transduction 
in HIVEP1 expression regulation and the influence of statins on the NF-κB binding affinity 
to the HIVEP1 promoter region could be confirmed in vivo by ChIP analyses performed 
with antibodies against different NF-κB family members in untreated or 
TNFα/statin-treated endothelial cells.  
To further determine the causal involvement of HIVEP1 in the pathophysiology of VT, 
HIVEP1 expression may be analyzed and compared in venous samples from VT patients 
and non-VT patients, whereby the potential use of statins has to be considered in the 
interpretation of the observed results. To definitely demonstrate the protective effect of 
statin therapy on VT and VTE, prospective controlled clinical studies should be conducted 
in individuals with predisposition (familial [genetic], susceptibility factor [e.g. HIVEP1]) to 
VT and VTE. The effect of each statin (rosuvastatin, simvastatin, atorvastatin, pravastatin) 
on VT/VTE and HIVEP1 expression will have to be documented. Patients groups should 
be divided into low- and high-dose statin users and the level of inflammatory markers 
should be documented to reveal potential paradoxical effects of statins as proposed in our 
current analysis. In addition, the effect of statin use in combination with vitamin K 
antagonists or new anticoagulants on VT/VTE should be studied in prospective clinical 
trials. An optimized therapeutic prevention of VT/VTE, which comprises certain statins in 
particular doses in combination with well-known anticoagulants, for individuals, which are 
characterized by certain biomarkers, e.g. HIVEP1 (predisposition to VT or VTE), could be 
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deduced from results obtained in prospective clinical studies performed as described 
above.   
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Figure A1: Endogenous expression of the TXA2 receptor in EA.hy926 cells Aspirin inhibits 
COX-1 leading to inhibition of TXA2 synthesis, a mediator of platelet aggregation and 
vasoconstriction. We observed endogenous expression of TXA2 in EA.hy926 cells, confirming that 
the components necessary for the aspirin pathway are present in EA.hy926 cells. PCR was 
performed after RNA isolation and cDNA generation using primers for both TXA2 receptor type α 
and β. 
 
 
 
 
 
 
 
 
Figure A2: Schematic representation of sequential detection of HIVEP1 transcripts in 
EA.hy926 and THP1 cells A) PCR fragments (dashed lines) were generated using 
sequence-specific primers based on HIVEP1 mRNA (NM_002114.2). B) HIVEP1 transcripts in 
EA.hy926 and THP1 cells deduced from sequential detection of HIVEP1 exons (white boxes) (A) 
and ENSEMBL database. Shaded box: alternative part of exon 5; *: exclusively in EA.hy926 cells.  
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Table A1: Oligonucleotides* used for sequential analysis of HIVEP1 transcripts  
Exons Sequence 5'-3' Amplicon size (bp) 
1a - 2 SS: CACTTCCAACCTAGGAGGC AS: CTCTTAGATTTCTGGGATGAATTTG 243 
1b - 2 SS: GCC CCA AAG ACG CTA AAC G AS: CTCTTAGATTTCTGGGATGAATTTG 192 
1c - 4♣$ SS: CGCCATCAGCAGCGCAGC AS: GCACTATGAAGAACGGCGAAAG 439 
4 SS: GCCTTCAGTTTCAGAATGCTCTG AS: GCTTGGGATCCATGGTCTGC 153 
4 - 6 SS: TTGCACTTGCTCTCCTTAATTC    AS: CAGTAAGTGCAGTGGTAGGG 411 
5 - 6 SS: TTCCTTTCAGAGAGCATTAGG AS: CTTTAGTCTTAAAGGAGAAGTTAC  325 
6 - 9 SS: GAGTATGTATATGTCCGAGGC AS: GCTATCACAAGCCTGTCCTCG 1948 
8$ SS: CAGAGATTCAGTTATGAGCGATC       AS: GTTATAGCAACAGCTTTTCCTGC       479 
* based on NM_002114.2  
♣ used for HIVEP1 endogenous expression PCR under basic and stimulatory conditions 
$ used for HIVEP1 knockdown monitoring 
SS: sense primer; AS: antisense primer  
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